Cryo-EM structure of the active, Gs-protein complexed, human CGRP receptor by Liang, Yi-Lynn et al.
Cryo-EM structure of the active, Gs-protein complexed, human CGRP receptor  1 
 2 
Yi-Lynn Liang1*, Maryam Khoshouei2*†, Giuseppe Deganutti3, Alisa Glukhova1, Cassandra 3 
Koole1, Thomas S. Peat4, Mazdak Radjainia1,5, Jürgen M. Plitzko2, Wolfgang Baumeister2, 4 
Laurence J. Miller1,6, Deborah L. Hay7, Arthur Christopoulos1, Christopher A Reynolds3, 5 
Denise Wootten1,8¶, Patrick M. Sexton1,8¶ 6 
 7 
1. Drug Discovery Biology and Department of Pharmacology, Monash Institute of 8 
Pharmaceutical Sciences, Monash University, Parkville 3052, Victoria, Australia.  9 
2. Department of Molecular Structural Biology, Max Planck Institute of Biochemistry, 82152 10 
Martinsried, Germany.  11 
3. School of Biological Sciences, University of Essex, Colchester CO4 3SQ, U.K. 12 
4. CSIRO Biomedical Manufacturing, Melbourne, Victoria 3052, Australia 13 
5. Thermo Fisher Scientific, 5651 GG Eindhoven, The Netherlands. 14 
6. Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, 15 
Scottsdale, Arizona 85259, U.S.A.  16 
7. School of Biological Sciences, and Maurice Wilkins Centre for Molecular Biodiscovery, 17 
University of Auckland, Auckland, New Zealand.  18 
8. School of Pharmacy, Fudan University, Shanghai 201203, China.  19 
 20 
†Current address: 21 
Novartis Institutes for Biomedical Research, Novartis Pharma AG, 4002 Basel, Switzerland 22 
 23 
*These authors contributed equally to this work. 24 
 25 
 26 
 ¶ To whom correspondence should be addressed:  27 
Patrick Sexton, Patrick.sexton@monash.edu   28 
Denise Wootten, denise.wootten@monash.edu   29 
 30 
 31 
 32 
  33 
SUMMARY 34 
Calcitonin gene-related peptide (CGRP) is a widely expressed neuropeptide that plays a 35 
major role in sensory neurotransmission. The CGRP receptor is a heterodimer of the 36 
calcitonin receptor-like receptor (CLR) class B G-protein-coupled receptor and the type 1 37 
transmembrane domain protein, receptor activity modifying protein (RAMP) 1. Herein, we 38 
report the 3.3 Å structure of the human CGRP receptor in complex with CGRP and the Gs-39 
protein heterotrimer determined by Volta phase plate cryo-electron microscopy. The 40 
RAMP transmembrane domain sits at the interface between transmembrane domains 3, 4 41 
and 5 of CLR, and stabilises CLR extracellular loop 2. RAMP1 makes only limited direct 42 
interaction with CGRP, consistent with allosteric modulation of CLR as its key function. 43 
Molecular dynamics simulations indicate that RAMP1 provides stability to the receptor 44 
complex, particularly the location of the CLR extracellular domain. The work provides 45 
novel insight into the control of G-protein-coupled receptor function. 46 
 47 
 48 
CGRP is a widely expressed sensory neuropeptide that has broad physiological functions. 49 
These include roles in modulation of metabolism, inflammatory response and blood 50 
pressure, as well as auditory nerve development and function1-4. It is a potent vasodilator 51 
that is released during neurogenic inflammation and contributes to the pathology of 52 
migraine. A first-in-class drug targeting the CGRP receptor was recently approved for 53 
treatment of this condition, and many other therapeutics are under development aimed at 54 
reducing CGRP activity5. In contrast, CGRP is protective in models of inflammatory bowel 55 
disease, and hypertension, and is a critical neuropeptide for development and modulation 56 
of auditory responses1-4.  57 
 58 
Receptor activity-modifying proteins (RAMPs), are essential accessory proteins for 59 
presentation of the class B calcitonin-like receptor (CLR) to the cell surface, and integral 60 
components of the phenotypically ascribed CGRP and adrenomedullin (AM) receptors, 61 
whereby CLR/RAMP1 engenders a selective response to CGRP, and CLR/RAMP2 or 62 
CLR/RAMP3, selective AM responses6. RAMPs are also partners for the calcitonin 63 
receptor (CTR), although not required for cell surface trafficking, they generate distinct 64 
amylin receptor (AMY) phenotypes1. Considerable cross talk between calcitonin-family 65 
peptides and receptors occurs, although current work has largely been restricted to how 66 
RAMPs impact cAMP signaling1. The three RAMPs each contain an ~100 amino acid, 67 
structured, N-terminal extracellular domain (ECD), a single TM domain and a short 68 
intracellular C-terminus. There is evidence that RAMPs co-evolved with GPCRs7; 69 
supporting this, we and others have shown that they can partner with numerous GPCRs, 70 
from all major subclasses, and are not exclusively partners for CLR and CTR8-11. 71 
 72 
Structures exist of heteromeric complexes of the isolated ECDs of RAMPs and CLR bound 73 
to C-terminal peptide fragments12,13. These structures have provided important but limited 74 
data on how RAMPs and CLR interact, and are unable to explain peptide selectivity.  75 
Thus, structures of full-length, active CGRP and AM receptor complexes are required to 76 
advance understanding. 77 
 78 
Recent advances in cryo-electron microscopy (cryo-EM) have allowed full-length, class B 79 
GPCR, peptide agonist-bound structures to be elucidated in complex with their canonical 80 
Gs-protein heterotrimers14-16. These studies revealed class-specific, conserved, global 81 
conformational changes linked to receptor activation, and unexpected divergence in the 82 
modes of peptide binding, even within the same receptor14-18. In the current work, we have 83 
used Volta phase plate (VPP) cryo-EM to determine the structure of the human CGRP 84 
receptor complex, bound to its endogenous peptide agonist and canonical transducer at a 85 
global resolution of 3.3 Å. This structure provides novel insights into how RAMPs interact 86 
with GPCRs and modulate their activity.  87 
 88 
Structure determination 89 
The CLR was modified to replace the native signal peptide with that of hemagglutinin (HA), 90 
and the addition of affinity tags bracketed by 3C cleavage sites at the N- and C-terminus 91 
(FLAG and His, respectively) (Ext. Data Figure 1). RAMP1 was modified to replace the 92 
native signal sequence with that of HA, followed by a FLAG epitope (Ext. Data Figure 1). 93 
These modifications did not alter receptor pharmacology (Ext. Data Figure 2A). 94 
 95 
To form an active, G protein-coupled complex, the CLR and RAMP1 were co-expressed 96 
with Gαs, His-Gβ1, and Gγ2 in Tni insect cells and stimulated with 10 μM CGRP. A 97 
stabilised Gαs15 was used enabling formation of a complex with improved stability19. 98 
Further complex stabilisation was achieved using camelid antibody Nb3514-16. The 99 
complex was treated with 3C enzyme to remove tags from CLR, solubilised in 100 
LMNG/cholesteryl hemisuccinate and then purified by sequential nickel and anti-FLAG 101 
columns, to ensure only RAMP1 bound complexes were present, and then further purified 102 
by SEC to yield a monodisperse complex that contained all components (Ext. Data Figure 103 
2B, 2C).  104 
 105 
Vitrified complexes were imaged in single particle cryo-EM using a Titan Krios microscope 106 
equipped with a VPP20,21. Following imaging (Ext. Data Figure 3A) and initial 2D 107 
classification (Ext. Data Figure 3B), 3D classification yielded a final map at a resolution of 108 
3.3Å reconstructed from 407,000 particle projections (Figure 1A; Ext. Data Figures 3C-109 
3E; Supp. Information Table 1). The cryo-EM density map exhibited well-resolved side 110 
chains, allowing confident rotamer placements for most amino acids within the peptide, 111 
receptor and RAMP TM domains and the G-protein (Ext. Data Figure 4). The RAMP and 112 
CLR ECDs had lower overall resolution, with discontinuous density for CLR ECD loop 1 113 
and loop 5 (Figure 1A; Ext. Data Figure 1; Ext. Data Figure 5). Nonetheless, there was 114 
a strong correlation between the ECD EM density and the individual ECDs of either CLR 115 
or RAMP1 in deposited X-ray structure (PDB: 4RWG12). As such, these were rigid body 116 
fitted into the ECD density, with side chain adjustment where this was supported by 117 
density in the EM map. While individual ECDs from the X-ray structures had close 118 
approximation to the EM map, there were distinctions in the relative positioning of the CLR 119 
and RAMP1 ECDs in the two structures (Ext. Data Figure 5) that likely arise from 120 
anchoring constraints of the transmembrane domains (TMs) in the full-length structure. 121 
Continuous density was observed for the RAMP1 ECD and TM, including the unstructured 122 
linker domain, but not for the short C-terminal tail (T144REGIV148R (superscript R refers to 123 
residues within RAMP1)), indicating that this is mobile in the active receptor complex 124 
(Figure 1). There was robust density for most of the TM core and loops of CLR, excepting 125 
segments of ECL3 and ICL3 that were omitted from the model (Figure 1; Ext. Data 126 
Figure 4). Additional density was observed adjacent to the base of TMs 2 and 4 that may 127 
represent lipid interaction with CLR (Ext. Data Figure 3G). There was a relatively short 128 
helix 8 (H8), with no density for the CLR C-terminus beyond Y4028.53 (receptor residues in 129 
superscript are defined using the class B numbering system22,14), while the far N-terminus 130 
of the ECD was also lacking density (Figure 1; Ext. Data Figure 1), indicating that these 131 
regions are also mobile. The CGRP peptide N-terminus (A1P-V23P (P in superscript refers 132 
to peptide residues)) that binds within the receptor core, was well defined in the map, while 133 
the majority of side chains in the peptide C-terminus (F27P-F37P) that interact exclusively 134 
with receptor ECDs, were also supported by density (Ext. Data Figure 4). Similar to 135 
salmon calcitonin (sCT) in the Gs-coupled CTR14 (Figure 4), there is a large kink in the 136 
peptide to enable interaction across the two receptor domains, with the CGRP linker 137 
(K24P-N26P) poorly resolved in the map. Within the receptor core, side chains that had 138 
limited density were stubbed in the model (Ext. Data Figure 1). There was well resolved 139 
density for the G-protein heterotrimer across the receptor interface and between subunits. 140 
The a-helical domain of the a-subunit was only present in a small number of the 2D class 141 
averages and was masked out during map refinement. In general, the regions of lower 142 
resolution or lacking density were segments of the complex that exhibited higher mobility 143 
in MD simulations of the full complex (Ext. Data Figure 6, Supp. Information Movies 1, 144 
2). 145 
 146 
The RAMP1 CLR interface 147 
The 2D class averages reveal that there is a single predominant orientation of the ECDs of 148 
the complex, relative to the CLR/RAMP core (Ext. Data Figure 3B). This contrasts to the 149 
variability in ECD orientation observed for the CTR14. RAMP1 makes extensive contacts 150 
with CLR with ~23% of its surface buried within this interface (Figure 1B, 1C). The 151 
extensive interface across the ECDs has been previously reported in X-ray crystal 152 
structures12,23. In contrast to predictions in published models of RAMPs with either CLR or 153 
CTR24-27, the RAMP1 TM sits at an interface formed by CLR TMs 3, 4 and 5, with 154 
interactions of the upper half principally with TM5 (T2885.33/ECL2, H2895.34/ECL2, I2935.38) 155 
(Figure 2A, 2B) and at the base with TM3 (L2313.48, I2353.52, T2393.56, V243ICL2) and TM4 156 
(W2544.44, Y2554.45, L2584.48, F2624.52) (Figure 2A, 2C). These interactions were primarily 157 
van der Waals interactions, although there was potential for H-bond formation between 158 
Y2554.45 and S141R. D113R in the membrane proximal segment of RAMP1 formed H-159 
bonds with ECL2 residues proximal to CLR TM4 (Y278ECL2), and TM5 (T2885.33, H2895.34) 160 
(Figure 2B). Alanine mutagenesis studies of CLR residues28-33 revealed decreased CGRP 161 
potency for the Y278ECL2, T2885.33/ECL2 and W2544.44 mutants with no impact on 162 
H2895.34/ECL2, I2935.38, T2393.56, V243ICL2 and Y2554.45 mutants32,33, consistent with 163 
important but weak interactions between RAMP1 and CLR. Likewise, there was a small 164 
decrease in CGRP potency with D113RA mutation indicating an indirect impact on CGRP 165 
peptide binding34. To understand the dynamics of the RAMP1/CLR interface we performed 166 
MD simulations, following modelling of missing amino acids and side chains into the full 167 
protein complex (Ext. Data Figure 7A, 7B; Supp. Information Table 2; Supp. 168 
Information Movie 1); these confirmed the importance of interactions between D113R and 169 
CLR ECL2 (Ext. Data Figure 7A). The simulations also predicted that E47ECD formed 170 
persistent H-bond interactions with R112R, in addition to H-bonds to the backbone of 171 
G108R and Ala110R in the linker region. R112R was also predicted to form less frequent H-172 
bonds with D90ECD but may maintain more persistent ionic interactions; collectively these 173 
interactions likely contribute to the limited mobility of the RAMP1 linker and stable 174 
positioning of the ECDs relative to the receptor core (Ext. Data Figure 7A; Supp. 175 
Information Table 2; Supp. Information Movies 2, 3). From the EM map, there were no 176 
resolved interactions between the RAMP and G-protein, however, there was no density for 177 
the RAMP1 C-tail. In MD simulations where the RAMP1 C-terminus was modelled 178 
transient interactions with ICL2, and the aN-helix of the Ga-protein were predicted, with 179 
potential interactions that could extend to ICL1 (Supp. Information Table 2). 180 
Nonetheless, this segment was highly mobile in the simulations. 181 
 182 
The CGRP binding site 183 
The CGRP peptide forms extensive interactions with the CLR/RAMP1 complex, with 184 
61.5% of its surface buried. Intriguingly, the only direct contact between the peptide and 185 
RAMP1 occurs at the far C-terminus of the peptide, principally with the cluster of RAMP 186 
residues (F83R-P85R) that have been previously observed in isolated ECD structures12 187 
(Figure 3A). The N-terminal peptide loop that is constrained by C2P-C7P is deeply buried, 188 
extending into an amphipathic a-helix, until V23P, that forms extensive van der Waal 189 
interactions (Figure 3D). There are only limited H-bonds in the static structure between the 190 
peptide N-terminus and the CLR core; these include interactions between Y2925.37 and the 191 
backbone of D3P, between H2955.40 and T6P, and S286ECL2 and the backbone of H10P 192 
(Figure 3C, 3D). Of these, only the interaction between H2955.40 and T6P is functionally 193 
important, with H2955.40A reported to cause ~30-fold loss of CGRP potency in cAMP 194 
accumulation28. This amino acid is equivalent to H3025.40 of the CTR that is predicted to 195 
form a H-bond with T6P of sCT14. Alanine substitution of CGRP T6P leads to ~80-fold loss 196 
of peptide potency29, confirming the importance of this bond and other interactions. There 197 
are extensive interactions between the peptide and TM3, TM5 and ECL2 of CLR. Below 198 
H2955.40, a series of amino acids that include I2985.43, L3025.47, M2233.40 and Y2273.44 form 199 
the bottom of the peptide binding pocket (Figure 3C, 3D; Ext. Data Figure 8B). Alanine 200 
substitution of T4P leads to over 20-fold reduction in CGRP potency29, however, it forms 201 
only limited interactions with the receptor. For this amino acid, side-chain to backbone 202 
interactions within the peptide that contribute to the loop fold and initiation of the peptide 203 
helix may underlie its functional importance. T9P and H10P pack within an extended cluster 204 
of residues that include T1912.64, L1952.68, H2193.36, S286ECL2, and I284ECL2 (Figure 3C; 205 
Ext. Data Figure 8B). With the exception of S286ECL2, alanine mutation of these residues 206 
caused marked impairment in CGRP signalling28,30-32 (Ext. Data Figure 8B), with I284ECL2 207 
and L1952.68 forming a hydrophobic barrier that coincides with the exit of the peptide from 208 
the receptor core (Ext. Data Figure 8B); MD simulations predict transient H-bond 209 
formation between T9P and H2193.36 (Ext. Data Figure 9E; Supp. Information Table 3). 210 
Alanine substitution of T9P causes a 15-fold loss of CGRP potency29, consistent with the 211 
importance of interaction of this side chain. While mutations to amino acids in the distal 212 
segment of ECL2 (S286ECL2, D287ECL2, H289ECL2, L2915.36) had relatively limited effects on 213 
CGRP potency28 (Ext. Data Figure 8B), ECL2 conformation is critical to CGRP activation 214 
of its receptor, with R2744.64 and, in particular, W283ECL2 mutation to alanine highly 215 
detrimental to CGRP signaling32 (Ext. Data Figure 8B). These amino acids are critical to 216 
the stable packing of ECL2 in the active structure, similar to those observed in other 217 
active, class B GPCR structures14-16. There are only limited contacts between ECL1 and 218 
the peptide, the most prevalent being between L16P, S17P and A199ECL1, N200ECL1, 219 
Q202ECL1 and V205ECL1 (Figure 3B; Ext. Data Figure 8B). Q202ECL1 is within weak H-220 
bond distance of the backbone oxygen of S17P (Ext. Data Figure 8B), however, alanine 221 
mutation of Q202ECL1, N200ECL1 or V205ECL1 had no impact on CGRP peptide potency, 222 
indicating limited importance of this domain for CGRP activity30. CLR and CTR have 223 
shorter ECL1 loops compared to the related glucagon (GCGR)35, or glucagon-related 224 
peptide 1 receptor (GLP-1R)15,16. These receptors have longer TM2 and TM3 helices (Ext. 225 
Data Figure 10A, 10B) that interact with the extended helix of peptide agonists of these 226 
receptors15,16,35. In the EM map, there was no high-resolution density for ECL3 consistent 227 
with only limited interaction between CGRP and this receptor segment. This high mobility 228 
and lack of persistent interactions was also observed in our MD simulations (Ext. Data 229 
Figure 9A-F); Supp. Information Table 3; Supp. Information Movie 2), while previously 230 
published alanine mutagenesis provides additional support for the limited role of this 231 
domain in CGRP-mediated cAMP production28,30 (Ext. Data Figure 8B).  232 
 233 
V8P, L12P and L16P lie on the same face of the peptide a-helix and sit deep within a 234 
groove formed by TMs 1 and 7, where they pack among multiple receptor residues. 235 
Alanine mutation of individual receptor amino acids within this groove have very little 236 
impact on CGRP-mediated cAMP production (Ext. Data Figure 8B), consistent with only 237 
weak contacts for individual amino acids. Nonetheless, alanine substitution of either L12P 238 
or L16P markedly impaired CGRP potency36, indicating that the packing of the hydrophobic 239 
face of the peptide helix is critical for receptor activation.  240 
 241 
In the EM structure, R11P forms polar interactions with the backbone of peptide residues 242 
T4P and C2P, with potential salt-bridge interactions with D3P and D3667.39 of the receptor, 243 
and may contribute to stability of the peptide loop conformation (Figure 3C). In MD 244 
simulations, R11P formed persistent H-bonds with D3667.39, though such interactions are 245 
not observed in the EM map. R18P is within salt-bridge distance to D287ECL2, and D90ECD, 246 
and forms a H-bond with D287ECL2 in nearly 25% of frames in the MD simulation (Figure 247 
3B, Ext Data Figure 9D, 9E).  248 
 249 
The resolution of the peptide C-terminus and receptor ECDs are lower than in the receptor 250 
core, and they were primarily modelled via rigid body fitting of the available x-ray structure 251 
(PDB: 4RWG12). To test the stability of interactions in the fully active structure, 6.4 µs MD 252 
simulations were run. Our data are consistent with the interactions previously reported in 253 
the isolated ECD structure12, and are summarised in Ext. Data Figure 9A-9F, and Supp. 254 
Information Table 3. The main intermolecular interactions involved T30P - D94ECD (Figure 255 
3B, Ext. Data Figure 9E), and F37P (amide terminus) - T122ECD (backbone atoms) (Ext. 256 
Data Figure 9E). There were no persistent hydrogen bonds between CGRP and RAMP1. 257 
The critical importance of interactions between the C-terminus of CGRP (F27P-F37P) and 258 
the CLR and RAMP1 ECDs for CGRP signaling has been highlighted by previous 259 
mutagenesis studies12,23,34,37,38, and are illustrated in Ext. Data Figure 8A. The extent to 260 
which this is dependent upon the stability of the relative positioning of the ECD to the 261 
receptor core is unclear, but RAMP1 is a major contributor to the limited conformational 262 
flexibility of the CLR ECD domain (Supp. Information Movie 3).  263 
 264 
Comparisons with the CTR structure 265 
CTR is most closely related to CLR, and both can interact with RAMP1 to form a high 266 
affinity CGRP receptor1. As such, we compared our previously published structure of the 267 
sCT:CTR:Gs complex to the CGRP receptor complex. Due to the relatively limited 268 
resolution in density for the peptide binding domain and N-terminus of the CTR, 269 
comparisons were limited to the backbone structures in these regions. Overall, there was a 270 
high degree of similarity between the CLR and CTR structures, both exhibiting an 271 
extended TM1 a-helical stalk that interconnects the receptor core and ECD, and a similar 272 
organization of the upper segments of TM6 and TM7, to accommodate the bulk of the 273 
cysteine-bridged loops of the peptides (Figure 4A).   274 
 275 
The largest difference was in the orientation of the ECD relative to the receptor core 276 
(Figure 4A, 4B). Intriguingly, this located the C-terminus of the peptides at virtually 277 
equivalent positions, with the N-terminal activation domain of the peptides also occupying 278 
a similar binding cavity (Figure 4B). Within the receptor core, there was an inward 279 
movement at the apex of TM5 of the CLR relative to CTR by ~2 Å, that is likely a product 280 
of the RAMP1 interaction with this domain (Figure 4C). There was a high degree of 281 
sequence conservation between CLR and CTR for the residues that contacted the RAMP 282 
(Figure 4D), which may explain the similar broad specificity for RAMP interaction of these 283 
receptors. We previously reported that, in simulations of the CTR bound to human CT 284 
(hCT) versus sCT, there was a surprising destabilization of ECL2 for hCT relative to the 285 
sCT bound receptor that was indicative of a role for conformational dynamics of this 286 
receptor domain in ligand interaction and efficacy18. The interactions of RAMP1 with ECL2 287 
may therefore contribute to peptide selectivity and/or efficacy. 288 
 289 
At the base of the receptor, the structured H8 of CLR was much shorter than that of CTR 290 
(Figure 4A), and consequently has more limited interaction with the Gb subunit. 291 
Nonetheless, truncation studies of the CTR C-terminus indicated that only the segment 292 
that is also present in the CGRP receptor structure was functionally important for Gs 293 
mediated signaling14. Perhaps more relevant, although the Gs-Ras a-H5 is aligned 294 
between the two structures, there are differences in the G-protein, particularly with respect 295 
to the positioning of the Gs-Ras a-N helix, which are propagated across the b- and g- 296 
subunits (Figure 4E).  297 
 298 
Broader comparison of Gs-protein interactions to include the active Gs-protein-coupled 299 
structures of the glucagon-like peptide-1 receptor (GLP-1R) bound to either exendin-P5 300 
(ExP5)15 or GLP-116 (Ext. Data Figure 10A, 10B), also revealed differences in the relative 301 
positioning of the Gs-protein, however, this was principally due to translational differences 302 
in the engagement of the receptors and the a-H5 (Ext. Data Figure 10C), with strong 303 
overlap in the backbone of the Ga subunit when these are aligned (Ext. Data Figure 304 
10D). ICL2 of CLR and CTR are longer than their GLP-1R counter parts, and there is an 305 
~2 Å greater outward movement of the base of TM6 of CLR and CTR compared to the 306 
GLP-1R (Ext. Data Figure 10A); these dissimilarities likely account for the translational 307 
differences in engagement of the Gs-protein by GLP-1R.  308 
 309 
Stability of the complex in the absence of RAMP1 310 
To help understand the contribution of RAMP1 to CGRP receptor function we performed 311 
MD simulations of the complex in the presence and absence of RAMP1. The orientation of 312 
the CLR ECD remains relatively stable during CLR-CGRP-RAMP1-Gabg-Nb35 (6.4 µs), 313 
and CLR-CGRP-RAMP1-miniGa (2 µs) MD simulations, but not during CLR-CGRP-314 
miniGa (2 µs) MD simulations, as shown in Supp. Information Movies 1-3. In the 315 
absence of RAMP1, only CGRP and TM1, with its extension, hold the ECD in place 316 
relative to the TM domain. The N-terminal region (A1P – R18P) of CGRP is stable (Supp. 317 
Information Movie 2), even in the absence of RAMP1, but the C-terminal region is 318 
affected by the mobility of the CLR ECD and is much more mobile in the absence of 319 
RAMP1 (Ext. Data Figure 6; Supp. Information Movie 3). A consequence of this C-320 
terminal mobility in the absence of RAMP1 is reduced persistence of H-bonds formed by 321 
CGRP in this region, as shown in Supp. Information Table 4.  322 
 323 
RAMP1 provides additional stability to ECL2, a major contact point for CGRP, even though 324 
this loop is relatively stable even in the absence of RAMP1. In the MD in the absence of 325 
RAMP1, there is a marked reduction in the persistence of H-bonds between R2744.64 and 326 
D280ECL2 (Supp. Information Table 5). In the cryo-EM structure, these two residues are 327 
able to form a salt-bridge interaction, and the stability of this interaction in the presence of 328 
RAMP1 is likely to impact on signal propagation. Indeed, mutagenesis of either of these 329 
residues greatly impacts CGRP mediated cAMP signalling28,32.  RAMP1 interaction does 330 
not impact the mobility of ECL1 and ICL3, and indeed there is no direct contact between 331 
the receptor and RAMP in these regions. The least mobile points of each TM generally 332 
correspond to point of helix intersection; for TM3 this is in the vicinity of Y2273.44, which 333 
provides a deep stable contact point for CGRP. 334 
 335 
It is important to note that, while these simulations provide insight into the contribution of 336 
RAMP1 to the preformed active complex, this complex does not form in the absence of 337 
RAMP, even where CLR is present at the cell surface6, indicating that the CLR/RAMP1 338 
interaction is also critical for initial peptide binding and presentation to the receptor core. 339 
 340 
In conclusion, the VPP cryo-EM structure of the CGRP-CLR-RAMP1-Gs complex provides 341 
unique insight into the organisation of functionally important heteromeric GPCR 342 
complexes. The RAMP1 causes marked stabilisation of the CLR ECD, and thus plays a 343 
critical role in ligand presentation to the receptor core. It further enhances stability of the 344 
TM domain interface and ECL2 that are important for propagation of peptide-induced 345 
signalling. This study provides a framework for the development of novel therapeutics that 346 
target the CGRP system. 347 
 348 
 349 
 350 
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  514 
FIGURE LEGENDS 515 
 516 
Figure 1 | The CGRP–CLR–RAMP1–Gs cryo-EM structure reveals molecular details 517 
of the RAMP-receptor interface. A, Left, 3.3 Å cryo-EM density map of the CGRP–CLR–518 
RAMP1–Gs complex; the detergent micelle has been masked out for clarity. Middle, 519 
structure in ribbon representation after refinement in the cryo-EM map; CGRP, dark red; 520 
CLR, blue; RAMP1, dark orange; Gas-Ras domain, gold; Gb-subunit, cyan; Gg-subunit, 521 
dark purple; Nb35, red. Right, cryo-EM density map coloured by local resolution (Å). B-C, 522 
CGRP receptor complex (ribbon representation coloured according to A), illustrating the 523 
extent of CLR interactions with other proteins in the complex (B), or the extent of RAMP1 524 
interactions with other proteins in the complex (C), shown in mauve coloured surface 525 
representation. CGRP and RAMP1 form extensive contacts with CLR, with 61.5% and 526 
23% of their surface buried, respectively. 527 
 528 
Figure 2 | RAMP1 forms stable interactions with the CLR core and ECD. A, The 529 
CGRP-CLR-RAMP1 complex, with the interacting residues depicted in x-stick 530 
representation, with the backbone shown in ribbon representation. CGRP, dark red; CLR, 531 
blue; RAMP1, dark orange. Regions amplified in B (red) and C (blue) are boxed. B, 532 
RAMP1 interacts with ECL2 and the top of TM5 towards the extracellular face of the 533 
receptor. C, RAMP1 interacts with TM3 and TM4 towards the intracellular face of the 534 
receptor; interacting side chains are depicted in x-stick representation and the backbone in 535 
ribbon.  536 
 537 
Figure 3 | The CGRP binding site. A, The CGRP interaction surface (amino acids within 538 
5 Å) of CLR (blue) or RAMP1 (dark orange), illustrating how the peptide N-terminus is 539 
buried within CLR. CGRP is shown in dark red surface representation. B-D, amino acid 540 
side chains of CLR proximal to CGRP residues; amino acids are shown in x-stick with 541 
carbons in blue (CLR) or dark red (CGRP), and other atoms coloured by type. B, CGRP 542 
L15P-V23P contact residues; T30P that forms two H-bonds with CLR D94ECD is also 543 
illustrated. C, CGRP V8P-G14P contact residues. D, CGRP A1P-C7P contact residues. 544 
There are very few H-bonds formed between the peptide N-terminus and CLR in the static 545 
structure.  546 
 547 
Figure 4 | The CTR and CGRP receptor complexes display similar backbone 548 
conformations but have distinct conformations of the Gas-Ras domain. A, Alignment 549 
of the CLR (blue ribbon)-RAMP1 (dark orange ribbon) and CTR (grey ribbon) structures; 550 
for the CTR the ECD is from the x-ray structure of the sCT-CTR x-ray structure (PDB: 551 
5II039), following rigid body fitting to the CTR EM map14. B, Zoom-in of the peptide binding 552 
sites; CGRP (dark red) and sCT (green) are shown as ribbon, CLR (blue) and CTR (grey) 553 
are shown as transparent ribbon. The circles highlight the similarities in position of the 554 
peptide N- (green) and C- (red) termini. RAMP1 has been omitted for clarity. C, Zoom-in 555 
illustrating distinctions in the upper segment of TM5 (red circle). D, Overlap in RAMP1 556 
contact residues between CLR (blue x-stick) and CTR (grey x-stick). E, The Gas-Ras-H5 557 
is superimposed in the two structures, but the a-H1 helix is in a different orientation (red 558 
circle) and leads to distinctions in positioning of the Gb and Gg subunits. The CTR G 559 
protein is shown as grey ribbon, the CGRP receptor G protein as coloured ribbon; Gas-560 
Ras (gold), Gb (cyan), Gg (dark purple). Regions of the receptor structures that are 561 
missing in the PDB files are shown as dashed lines. 562 
 563 
 564 
 565 
 566 
 567 
 568 
 569 
METHODS 570 
 571 
Constructs. CLR was modified to include an N-terminal Flag tag epitope and a C-terminal 572 
8xhistidine tag, both tags are removable by 3C protease cleavage. The construct was 573 
generated in both mammalian and insect cell expression vectors.  RAMP1 was modified to 574 
include an N-terminal Flag tag epitope. For both constructs, the natural signal peptide was 575 
replaced with that of hemagglutinin to improve expression (Ext. Data Figure 1).   576 
 577 
Insect cell expression. CLR, RAMP1, DNGαs15, His6-tagged human Gβ1and Gγ2were 578 
expressed in Tni insect cells (Expression systems) using baculovirus.  Cell cultures were 579 
grown in ESF 921 serum-free media (Expression Systems) to a density of 4 million cells 580 
per ml and then infected with three separate baculoviruses at a ratio of 1:5:2:1 for CLR, 581 
RAMP1, DNGαs and Gβ1γ2. Culture was harvested by centrifugation 48 h post infection and 582 
cell pellet was stored at -80 °C.   583 
 584 
Complex purification. Cell pellet was thawed in 20 mM HEPES pH 7.4, 50 mM NaCl, 2 585 
mM MgCl2 supplemented with cOmplete Protease Inhibitor Cocktail tablets (Roche). 586 
Complex formation was initiated by addition of 10 μM human aCGRP (Chinapeptide), 587 
Nb35–His (10 μg/mL), 3C protease (10 μg/mL) and Apyrase (25 mU/mL, NEB); the 588 
suspension was incubated for 1 h at room temperature. Membranes were collected by 589 
centrifugation at 30,000g for 30 min. Complexes from membranes were solubilized by 590 
0.5% (w/v) lauryl maltose neopentyl glycol (LMNG, Anatrace) supplemented with 0.03% 591 
(w/v) cholesteryl hemisuccinate (CHS, Anatrace) for 2 h at 4 °C in the presence of 1 μM 592 
CGRP and apyrase (25 mU/mL, NEB). Insoluble material was removed by centrifugation 593 
at 30,000g for 30 min and the solubilized complex was immobilized by batch binding to 594 
NiNTA resin. The resin was packed into a glass column and washed with 20 column 595 
volumes of 20mM HEPES pH 7.4, 100 mM NaCl, 2 mM MgCl2, 0.01% (w/v) LMNG and 596 
0.006% (w/v) CHS, 1μM CGRP, before bound material was eluted in buffer containing 250 597 
mM imidazole. The NiNTA purified fraction was immobilized by batch binding to M1 anti-598 
FLAG affinity resin in the presence of 3 mM CaCl2. The resin was packed into a glass 599 
column and washed with 20 column volumes of 20 mM HEPES pH 7.4, 100 mM NaCl, 2 600 
mM MgCl2, 3 mM CaCl2, 1 μM CGRP, 0.01% (w/v) LMNG and 0.006% (w/v) CHS before 601 
bound material was eluted in buffer containing 5 mM EGTA and 0.1 mg/mL FLAG peptide. 602 
The complex was then concentrated using an Amicon Ultra Centrifugal Filter (MWCO 100 603 
kDa) and subjected to size-exclusion chromatography on a Superose 6 Increase 10/300 604 
column (GE Healthcare) that was pre-equilibrated with 20 mM HEPES pH 7.4, 100 mM 605 
NaCl, 2 mM MgCl2, 1 μM CGRP, 0.01% (w/v) LMNG and 0.006% (w/v) CHS. Eluted 606 
fractions consisting of receptor and G-protein complex were pooled and concentrated. 607 
Final yield of purified complex was approximately 0.3 mg per liter of insect cell culture. 608 
 609 
SDS–PAGE and western blot analysis. Sample collected from size-exclusion 610 
chromatography was analyzed by SDS–PAGE and Western blot as previously 611 
described15. For SDS–PAGE, precast gradient TGX gels (Bio-Rad) were used. The final 612 
SEC elution peak was stained by Instant Blue (Expedeon).   613 
 614 
Modelling into EM density. An initial template for CLR was generated by homology 615 
modelling on template cryo-EM structure of hCTR (PDB-5UZ7)14, performed with the 616 
Molsoft ICM modelling software40. Manual adjustment and rebuilding was performed in 617 
COOT41. Due to limited density in CLR and RAMP1 ECD regions, we used the high-618 
resolution X-ray crystal structure (PDB-4RWG)12 for modelling.  ECDs of CLR and RAMP1 619 
were, separately, rigid body fitted into density prior to the final iteration of global 620 
refinement. DNGαs, Gβ1, Gγ2 and Nb35 models were taken from the GLP1R-Gs-ExP5 621 
structure (PDB-6B3J)15. The CGRP peptide and RAMP1 TM were modeled manually. The 622 
final model was subjected to global refinement and minimization in real space using the 623 
module ‘phenix.real_space_refine’ in PHENIX42. Validation was performed in MolProbity43. 624 
 625 
Preparation of vitrified specimen. EM grids (Quantifoil, Großlöbichau, Germany, 200 626 
mesh copper R1.2/1.3) were glow discharged for 30 s using Harrick plasma cleaner 627 
(Harrick, Ithaca, NY). 4 µl of sample was applied on the grid in the Vitrobot Mark IV 628 
chamber (Thermo Fisher Scientific, Waltham, MA). The chamber of Vitrobot was set to 629 
100% humidity at 4 °C. The sample was blotted for 4.5 s with blot force of 20 and then 630 
plunged into propane-ethane mixture (37% ethane and 63% propane). 631 
 632 
Data acquisition. Data set was collected on a Thermo Fisher Scientific Titan Krios 633 
microscope operated at 300 kV (FEI, Hillsboro, OR) equipped with a Gatan Quantum 634 
energy filter, a Gatan K2 summit direct electron camera (Gatan, Pleasanton, CA) and a 635 
Volta phase plate (Thermo Fisher Scientific). Movies were taken in EFTEM nanoprobe 636 
mode, with 50 µm C2 aperture, at a calibrated magnification of 47170 corresponding to a 637 
magnified pixel size of 1.06 Å. Each movie comprises 50 sub frames with a total dose of 638 
50 e-/Å2, exposure time was 13 s with the dose rate of 4.8 e-/pix/s on the detector. Data 639 
acquisition was done using SerialEM software at -600 nm defocus44. 640 
 641 
Data processing. 3180 movies were collected and subjected for motion correction using 642 
MotionCor245. CTF estimation was done using Gctf software46 on non-dose-weighted 643 
micrographs. The particles were picked using Gautomatch (developed by Dr Kai Zhang, 644 
MRC Laboratory of Molecular Biology, Cambridge, UK, http://www.mrc-645 
lmb.cam.ac.uk/kzhang/Gautomatch/). An initial model was made using the common-line 646 
approach in EMAN247 based on automatically picked few micrographs and using the 647 
common-line approach. The particles were extracted in RELION 2.01b148 using a box size 648 
of 200 pixels. 1,205,000 picked particles were subjected to 2D classification with 100 649 
classes, followed by 3D classification. After selecting the best-looking class, with 407,000 650 
particles, 3D auto-refinement was performed in RELION 2.01b1. The final map was 651 
sharpened with a B-factor of -50 Å2. The processing workflow is outlined in Ext. Data 652 
Figure 3C. Model overfitting was evaluated by randomly displacing all atoms by 0.5Å and 653 
refined against one cryo-EM half map.  FSC curves were calculated between the resulting 654 
model and the half map used for refinement, the resulting model and the other half map for 655 
cross validation, and the final refined model and the full map (Ext. Data Figure 3F).  656 
 657 
Mammalian cell cAMP assays. Cos7 cells, which were confirmed to be free from 658 
mycoplasma, were transfected in suspension in 96 well plates (10,000 cells/well) with 659 
50ng CLR + 50ng human RAMP1 using 600ng PEI. The transfection was performed in 5% 660 
FBS DMEM, 200uL total volume per well and cells were incubated for 48 h at 37°C, 5% 661 
CO2. cAMP detection was performed as previously described49. All values were converted 662 
to cAMP concentration using a cAMP standard curve performed in parallel and data were 663 
subsequently normalized to the response of 100 µM forskolin. 664 
 665 
Conformational clustering of CGRP ECL3 and the RAMP1. The missing loops 666 
throughout CLR were generated using PLOP50, which has been shown to be effective in 667 
generating GPCR loop conformations51. The missing side chains were iteratively optimized 668 
to convergence using PLOP. In addition, in order to enhance the conformational sampling 669 
of ECL3, which is likely to interact with the CGRP peptide, a preliminary clustering of 4000 670 
different loop models generated using Modeller 9.1652 was performed by means of the 671 
Clustering VMD plugin (available at http://physiology.med.cornell.edu/ 672 
faculty/hweinstein/vmdplugins/clustering/). Conformational clustering was based on the 673 
coordinates of side chains belonging to residues W3546.58, R3556.59, P356ECL3, E357ECL3, 674 
K359ECL3, I360ECL3, A361ECL3 and E362ECL3. A total of 10 clusters were generated with a 675 
Root Mean Standard Deviation (RMSD) cut off value of 3 Å and a representative structure 676 
with a low Distributed Optimized Potential Energy (DOPE) score from the four most 677 
populated ensembles was extracted and prepared for molecular dynamics simulations. 678 
A similar approach was employed for clustering the modelled RAMP1 C-terminus 679 
(residues T144R, - V148R): the original PLOP generated conformation was combined with 680 
each of the 4 initially selected ECL3 conformations, while the highly distinct RAMP1 C-681 
terminus orientation was arbitrarily combined with ECL3 conformation number 1. 682 
 683 
Molecular dynamics (MD) simulations. A total of seven systems were prepared for MD 684 
simulations with the CHARMM36 force field53 (Supp. Information Table 6) using a 685 
multistep procedure that combines python htmd54 and tcl (Tool Command Language) 686 
scripts. Hydrogen atoms were first added by means of the pdb2pqr55 and propka56 687 
software (considering a simulated pH of 7.0); the protonation of titratable side chains was 688 
checked by visual inspection. CLR and RAMP1 were embedded in a square 116 Å x 116 689 
Å 1-palmitoyl-2-oleyl-sn-glycerol-3-phospho-choline (POPC) bilayer (previously built by 690 
using the VMD Membrane Builder plugin 1.1, at 691 
http://www.ks.uiuc.edu/Research/vmd/plugins/membrane/) through an insertion method57. 692 
More precisely, the opportune receptor orientation was obtained by superposing CLR 693 
coordinates on the CTR structure retrieved from the OPM database58. Lipids overlapping 694 
the receptor TMs bundle and the RAMP1 were removed and TIP3P water molecules59 695 
were added to the simulation box (116 Å x 116 Å x 185 Å) by means of the VMD Solvate 696 
plugin 1.5 (Solvate Plugin, Version 1.5. at 697 
<http://www.ks.uiuc.edu/Research/vmd/plugins/solvate/). Overall charge neutrality was 698 
finally reached by adding Na+/Cl- counter ions (final ionic strength of 0.150 M), using the 699 
VMD Autoionize plugin 1.3 (Autoionize Plugin, Version 1.3. at 700 
<http://www.ks.uiuc.edu/Research/vmd/plugins/autoionize/).  701 
In order to evaluate the influence exerted by RAMP1 on the CGRP-CLR complex, 702 
two simplified systems were embedded in a 96 Å x 96 Å POPC bilayers and solvated as 703 
described above: one was composed by CLR-CGRP-RAMP1 and the C-terminus 704 
(residues N371G - L394G) of the G-protein α subunit (CLR-CGRP-RAMP1-G-protein(a371-705 
394), while the other system was formed by CLR-CGRP and the C-terminus of the G-706 
protein α subunit (CLR-CGRP-G-protein(a371-394); the original PLOP generated 707 
conformations of CLR and RAMP1 were used. 708 
 709 
Systems equilibration and MD settings. The MD engine ACEMD60 was employed for 710 
both the equilibration and productive simulations. Equilibration was achieved in isothermal-711 
isobaric conditions (NPT) using the Berendsen barostat61 (target pressure 1 atm) and the 712 
Langevin thermostat62 (target temperature 300 K) with a low damping of 1 ps-1. A three-713 
stage procedure was performed (integration time step of 2 fs): first, clashes between 714 
protein and lipid atoms were reduced through 2500 conjugate-gradient minimization steps, 715 
then a 2 ns long MD simulation was run with a positional constraint of 1 kcal mol-1 Å-2 on 716 
protein and lipid phosphorus atoms. During the second stage, 40 ns of MD simulation were 717 
performed constraining only the protein atoms, while in the last equilibration stage, 718 
positional constraints were applied only to the protein backbone alpha carbons, for a 719 
further 5 ns. 720 
Supp. Information Table 6 summarizes all the simulations performed. Trajectories 721 
were computed with an integration time step of 4 fs in the canonical ensemble (NVT) at 722 
300 K, using a thermostat damping of 0.1 ps-1 and the M-SHAKE algorithm63 to constrain 723 
the bond lengths involving hydrogen atoms. The cut off distance for electrostatic 724 
interactions was set at 9 Å, with a switching function applied beyond 7.5 Å. Long range 725 
Coulomb interactions were handled using the particle mesh Ewald summation method 726 
(PME)64 by setting the mesh spacing to 1.0 Å. 727 
 728 
MD analysis. Atomic contacts, hydrogen bonds and Root Mean Square Fluctuation 729 
(RMSF) were computed using VMD65. A contact was considered productive if the distance 730 
between two atoms was lower than 3.5 Å. For hydrogen bond detection, a donor-acceptor 731 
distance of 3 Å and an angle value of 160° were set as geometrical cut-offs. The hydrogen 732 
bond persistence is defined as the number of frames in which the H-Bond is formed 733 
divided by the total number of frames times 100. The RAMP1 influence on van der Walls 734 
contacts and hydrogen bonds was evaluated by computing the numerical difference 735 
between the total numbers of contacts/hydrogen bonds between each CLR and CGRP 736 
side chain during the simulations in presence and absence of RAMP1.  737 
 738 
Data availability. All relevant data are available from the authors and/or included in the 739 
manuscript or Supplementary Information. Atomic coordinates and the cryo-EM density 740 
map have been deposited in the Protein Data Bank (PDB) under accession number 6E3Y 741 
and EMDB entry ID EMD-8978. 742 
 743 
Extended Data Figure 1 | Amino acid sequences of the CGRP peptide, CLR and 744 
RAMP1 constructs use for determination of structure. The sequences are annotated 745 
to denote the location of the HA signal sequence (red highlight), C3 cleavage sites (grey 746 
highlight), FLAG (dark olive-green highlight) and His tags (purple highlight). The 747 
substituted sequences of the native proteins are listed above the construct sequences and 748 
highlighted in blue. Transmembrane helical domains in CLR and RAMP1 are boxed and 749 
highlighted in green. Segments of the proteins that were not resolved in the EM map are 750 
highlighted in yellow. Amino acids for which backbone density was present but limited side 751 
chain density, were stubbed in the model; these are bolded in red in the sequences. 752 
 753 
Extended Data Figure 2 | CGRP receptor pharmacology and purification of the 754 
CGRP-CLR-RAMP1-Gs complex. A; Pharmacology of untagged CLR-RAMP1 (WT CLR-755 
RAMP1) and the purification construct (HA–FLAG-CLR, FLAG-RAMP1), in CGRP-756 
mediated cAMP accumulation assays performed in transiently transfected Cos7 cells (N=5 757 
separate experiments with triplicate repeats; mean + s.e.). B; Expression and purification 758 
strategy. C; Final size exclusion chromatography (SEC) elution profile of the complex. D; 759 
SDS–PAGE/Coomassie blue stain of the SEC peak, demonstrating presence of each of 760 
the components of the complex. 761 
 762 
Extended Data Figure 3 | Volta phase plate imaging of the CGRP–CLR–RAMP1-Gs 763 
heterotrimer complex. A; Volta phase plate micrograph of the complex (representative of 764 
3,180). High-contrast phase plate imaging facilitates robust particle selection despite low 765 
defocus and tight packing of particles. B; RELION 2D class averages. C; Workflow for map 766 
refinement. D; Final 3D EM map calculated in RELION after auto-refinement and map 767 
sharpening. E; ‘gold standard’ Fourier shell correlation (FSC) curve; the overall nominal 768 
resolution is 3.26 Å. F; Model overfitting was evaluated by randomly displacing all atoms 769 
by 0.5Å and refined against one cryo-EM half map. FSC curves were calculated between 770 
the resulting model and the half map used for refinement (green); the resulting model and 771 
the other half map for cross validation (red), and the final refined model and the full map 772 
(blue). G; Potential lipid interaction with the base of TM4 and TM2 of CLR. 773 
 774 
Extended Data Figure 4 | Atomic resolution model of the CGRP–CLR–RAMP1-Gs 775 
heterotrimer in the cryo-EM density map. EM density map and model are shown for all 776 
seven transmembrane helices and H8 of the receptor, the CGRP peptide (excepting the 777 
K24PA25PN26P sequence that was not resolved in the map), the RAMP TM and each of 778 
the RAMP ECD helices; there was only limited side chain density for RAMP1 H1, with side 779 
chains modeled from rigid body fitting of the RAMP1 ECD in PDB: 4RWG12. Also 780 
illustrated are the N-terminal (aH1) and C-terminal (aH5) a-helices of the Gas-Ras 781 
domain. 782 
 783 
Extended Data Figure 5 | Comparison of the backbone position of the ECD of CLR 784 
(blue ribbon) and RAMP1 (orange ribbon) from the modelled, active complex, and 785 
the structure of the isolated CLR-RAMP1 ECD complex solved by x-ray 786 
crystallography12 (light grey ribbon). The structures were aligned on the RAMP1 ECD. 787 
The CLR loops (Loops 1 – 5) are annotated. The CLR loop1 and loop 5 sequences that 788 
were not resolved in the EM map are indicated by dotted black arrows. Differences in the 789 
backbone position of CLR loops 4 and 5 are indicated in blue (active complex) and grey 790 
(isolated ECD complex) dotted arrows. The location of the CGRP peptide is shown in dark 791 
red.  792 
 793 
Extended Data Figure 6 | Root mean square fluctuation (RMSF) for CGRP and CLR 794 
taken from the three simulations, namely CLR-CGRP-RAMP1-Gabg-Nb35 (black, 2.4 795 
µs), CLR-CGRP-RAMP1-Ga(371-394) (purple, 2 µs) and CLR-CGRP-Ga(371-394) (blue, 796 
2 µs). A; The CLR ECD region. B; the CLR TM region. C; CGRP (superposed on Thr6-797 
Ser17 and so valid for N-terminal half). In general, the missing segments in the EM density 798 
map correspond to regions of high RMSF and indeed the difficulty of fitting the ECD as a 799 
whole is linked to its high RMSF (A; Supp. Information Movies 2, 3). The ECD missing 800 
segments (D55ECD-V63ECD) and (Q107ECD-G109ECD) correspond to external loop regions 801 
furthest removed from the TM domain. Despite their polar nature they displayed no 802 
persistent interactions during the MD simulations; D55ECD-V63ECD displayed the largest 803 
backbone RMSF of 8Å, while Q107ECD-G109ECD displayed a similarly high RMSF of 7.5 Å. 804 
The next highest RMSF peaks around A79ECD-G81ECD and P115ECD-S117ECD are just a 805 
little lower but are nonetheless resolved (A). Within the TM domain, ICL3 (H324-S328) and 806 
ECL3 (P356-E362) both contain missing residues and have a high RMSF above 4.5 Å (B). 807 
This region displays no persistent interactions during the MD simulations, although CGRP 808 
does interact to the proximal (non-missing) region of ECL3. The high RMSF values for 809 
ICL1 (3.6 Å) and ICL2 (3.6 Å) give rise to stubbed residues (K1672.40) and E248ICL2-810 
Q250ICL2) but the backbone is resolved. For CGRP, the peak in the RMSF around residue 811 
26 (C) corresponds to the three highly mobile external residues (Lys24Asn25Asn26) in the 812 
outward-facing loop that do not interact with CLR (Ext. Data Figure 8); these residues 813 
could not be placed from the electron density. These three CGRP residues form a hinge, 814 
enabling changes in the orientation of the CLR ECD, especially in the absence of RAMP1; 815 
the higher RMSF values C-terminal to this are an artefact of the superposition strategy and 816 
the two-domain nature of CLR but their relative values still hold. The high mobility of some 817 
of the extracellular loops is visible in movies (Supp. Information Movies 1-3).  818 
 819 
Extended Data Figure 7 | RAMP1 makes extensive stable interactions with CLR. A; 820 
Hydrogen bonds between RAMP1 and CLR during MD simulations (6.4 µs). The total 821 
persistency is plotted onto the experimental structure according to a rainbow colour scale, 822 
with residues never involved in dark blue and residue highly involved in red. The receptor 823 
is shown as a bulky ribbon, the RAMP1 as a thin coloured ribbon and the peptide as a thin 824 
white ribbon. Key side chains are shown, but for intermittent hydrogen bonds the rotameric 825 
state has been modified to show an interaction. Residues forming an interaction network 826 
are labelled with the same colour. Left, overall topology of the system. Right upper, zoom 827 
on the upper portion of the CLR TM domain and ECD; lower, view rotated by 90° on the z 828 
axis. H-bonds involving RAMP1-CLR residues R112R-E47ECD and D113R-829 
T288ECL2/H289ECL2 are significant for linking the TM domain to the ECD and for stabilizing 830 
ECL2. Other H-bonds implicated in stabilizing the CLR and RAMP1 ECD interaction 831 
include S107R-E47ECD, R102R-D55ECD, H97R- Q50ECD, D90R-Y49ECD, D71R-R38ECD and 832 
E29R-R119ECD; quantitative data on the persistence of H-bonds during the simulations are 833 
reported in Supp. Information Table 2. B; Contacts between RAMP1 and CLR during MD 834 
simulations (6.4 µs). The total persistency of a residue side chain is plotted onto the 835 
experimental structure according to a cyan-maroon colour scale, with residues never 836 
involved in cyan and residue highly involved in maroon. The peptide (italics, dashed line) 837 
is depicted as a thin ribbon, while the receptor (solid line) is shown as a bulky ribbon and 838 
transparent surface. Left, overall topology of the system. Upper right, the most persistent 839 
interactions involving RAMP residues and the CLR ECD, W59R, I63R, Y66R, H97R and 840 
I106R help to anchor aH3 and the C-terminal RAMP1 regions of aH2 to (residues M42ECD, 841 
T43ECD, Y46ECD, Y49ECD, Q50ECD, and M53ECD, of the CLR ECD). Lower right, the most 842 
persistent hydrophobic interactions between the TM domains of RAMP1 and CLR, namely 843 
I123R, P126R, T130R, T134R, and V137R (plus S141R) help to anchor the RAMP 844 
transmembrane helix to CLR (TM3-TM5; CLR residues Y277ECL2, H289ECL2, A3005.45, 845 
I2353.52, F2624.52, L2584.48 and W2544.44).  846 
 847 
Extended Data Figure 8 | Effect of alanine mutagenesis of CLR or RAMP1 on CGRP 848 
potency in cAMP accumulation assays. A; ECD alanine mutations. B; CLR core alanine 849 
mutations. Residues that have been mutated are displayed in x-stick format. Mutated 850 
residues with no effect on signalling are coloured off-white. Residues that have 851 
significantly altered CGRP signaling12,23,28,30-32,34,37,38 are also highlighted in transparent 852 
CPK representation, coloured according to magnitude of effect. <10 fold, yellow; 10-100 853 
fold, dark orange; 100-1000 fold, red; >1000 fold, black. The backbones of CLR and 854 
RAMP (solid lines) are displayed in transparent, off-white coloured ribbon. The CGRP 855 
peptide (dashed lines) is represented in x-stick format with carbon atoms in dark red and 856 
polar atoms coloured in red or blue. 857 
 858 
Extended Data Figure 9 | CGRP makes extensive stable interactions with CLR. A-D; 859 
Distances between CGRP and CLR residues relevant to key hydrogen bonds. The x-axis 860 
denotes sampling time for the 16 merged MD replicas of the whole system (each replica is 861 
separated by vertical dashed lines). A; Distance between the peptide D3P carboxylic 862 
carbon and receptor R3556.59 guanidinium carbon. B; distance between the peptide T6P 863 
side chain oxygen atom and the receptor H2955.40 side chain nitrogen atoms (for each 864 
frame, the closest nitrogen to T6P was considered). C; Distance between the peptide R11P 865 
guanidinium carbon and the receptor D3667.39 carboxylic carbon. D; Distance between 866 
peptide R18P guanidinium carbon and receptor D287ECL2 carboxylic carbon. In most cases 867 
the distances corresponding to hydrogen bond formation are slightly longer than the 868 
standard 2.8 Å. E; H-bonds between CGRP and CLR during MD simulations (6.4 µs). The 869 
total persistency of a residue side chain is plotted onto the experimental structure 870 
according to a rainbow colour scale, with residues never involved in blue and residues 871 
highly involved in red. The peptide (italics, dashed line) is depicted as thin ribbon, while 872 
the receptor (solid line) is shown as bulky ribbon. Key side chains are shown, but for 873 
intermittent H-bonds the rotameric state has been modified to show an interaction. 874 
Residues forming an interaction network are labelled with the same colour. Lower panel, 875 
H-bonds between the CGRP N-terminus and the TM bundle of CLR. Upper panel, H-876 
bonds between the CGRP C-terminus and the ECD of CLR; quantitative data on the 877 
persistence of H-bonds during the simulations are reported in Supp. Information Table 3. 878 
 F; Contacts between CGRP and CLR / RAMP1 during MD simulations (6.4 µs). The total 879 
persistency of a residue side chain is plotted onto the experimental structure according to 880 
a cyan-maroon colour scale, with residues never involved in cyan and residue highly 881 
involved in maroon. The peptide (italics, dashed line) is depicted as a thin ribbon, while the 882 
receptor (solid line) is shown as a bulky ribbon and transparent surface. Left, contacts 883 
between the N-terminus of CGRP and the TM bundle of the CLR: highly persistent 884 
hydrophobic interactions characterize peptide residues L12P, L16P, H10P and receptor 885 
residues L1952.68, A1381.36 and H2955.40. Right, contacts between the C-terminus of CGRP 886 
and the ECD of CLR; highly persistent contacts characterize peptide residues V32P, T30P, 887 
F37P and receptor residues Q93ECD and W72ECD. RAMP1 residues F83R, W84R are mainly 888 
engaged by CGRP residue F37P.  889 
 890 
Extended Data Figure 10 | Class B GPCRs display similar active state 891 
conformations. A-B; Alignment of the CGRP-CLR-RAMP1, sCT-CTR, ExP5-GLP-1R and 892 
GLP-1-GLP1R structures (aligned on the TM domains). Regions of divergence between 893 
CLR/CTR and GLP-1R are circled. In A, RAMP1 has been omitted for clarity. C; Position 894 
of the Gas-Ras domain in the CTR (left), GLP-1R (GLP-1 bound; middle) and GLP-1R 895 
(ExP5 bound; right). The receptor TMs were aligned. Only the CLR (blue) and RAMP1 896 
(orange) are displayed for clarity. D; The Gas-Ras domain from each of the four 897 
structures, aligned according to the Gas-Ras. 898 
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Supporting Information Table 2. Persistence of H-bonds and other contacts 977 
between RAMP1 and CLR in MD simulations. 978 
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Supporting Information Table 3. Persistence of H-bonds and other contacts 980 
between CGRP and CLR or RAMP1 in MD simulations. 981 
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Supporting Information Table 4. The difference in hydrogen bond formation 983 
between CGRP and CLR, during MD simulations performed on the CGRP-CLR-984 
Ga(371-394) complex in the presence and absence of RAMP1. 985 
 986 
Supporting Information Table 5. The difference in CLR intra-molecular hydrogen 987 
bonds formation in the presence or absence of RAMP1.  988 
 989 
Supporting Information Table 6. Summary of all the MD simulations performed on 990 
the CLR-CGRP-RAMP1-G-protein.  991 
 992 
Supporting Information Movie 1. 993 
The CGRP (grey), CLR (green), RAMP1 (orange), G-protein (a subunit in blue, b 994 
subunit in red and g subunit in yellow), Nb35 (maroon) complex simulated during a 995 
400 ns long MD replica. Water molecules, ions and the lipid bilayer have been 996 
removed for clarity. 997 
 998 
Supporting Information Movie 2. 999 
Details of the extracellular TMs bundle during a 500 ns long MD replica, performed 1000 
on the CGRP-CLR-RAMP1-G-protein complex. The hydrogen bonds formed 1001 
between CGRP (orange), and CLR (cyan), and between CGRP (orange) and 1002 
RAMP1 (green) are highlighted as dotted lines throughout the simulation. 1003 
 1004 
Supporting Information Movie 3. 1005 
Comparison between two different 500 ns long MD simulations performed on: Left, 1006 
CGRP (orange), CLR (green ribbon and transparent surface), RAMP1 (magenta 1007 
ribbon and transparent surface), G-protein (371-394) complex. Right, CGRP 1008 
(orange), CLR (green ribbon and transparent surface), G-protein (371-394) complex. 1009 
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SUPPORTING INFORMATION 
Supporting Information Table 1. A, PDB validation report. B, Cryo-EM data collection, 
refinement and validation statistics. 
Supporting Information Table 2. Persistence of H-bonds and other contacts between 
RAMP1 and CLR in MD simulations. 
Supporting Information Table 3. Persistence of H-bonds and other contacts between 
CGRP and CLR or RAMP1 in MD simulations. 
Supporting Information Table 4. The difference in hydrogen bond formation between 
CGRP and CLR, during MD simulations performed on the CGRP-CLR-Ga(371-394) 
complex in the presence and absence of RAMP1. 
Supporting Information Table 5. The difference in CLR intra-molecular hydrogen bonds 
formation in the presence or absence of RAMP1.  
Supporting Information Table 6. Summary of all the MD simulations performed on the 
CLR-CGRP-RAMP1-G-protein.  
Supporting Information Movie 1. 
The CGRP (grey), CLR (green), RAMP1 (orange), G-protein (a subunit in blue, b subunit in 
red and g subunit in yellow), Nb35 (maroon) complex simulated during a 400 ns long MD 
replica. Water molecules, ions and the lipid bilayer have been removed for clarity. 
Supporting Information Movie 2. 
Details of the extracellular TMs bundle during a 500 ns long MD replica, performed on the 
CGRP-CLR-RAMP1-G-protein complex. The hydrogen bonds formed between CGRP 
(orange), and CLR (cyan), and between CGRP (orange) and RAMP1 (green) are highlighted 
as dotted lines throughout the simulation. 
Supporting Information Movie 3. 
Comparison between two different 500 ns long MD simulations performed on: Left, CGRP 
(orange), CLR (green ribbon and transparent surface), RAMP1 (magenta ribbon and 
transparent surface), G-protein (371-394) complex. Right, CGRP (orange), CLR (green 
ribbon and transparent surface), G-protein (371-394) complex. 
Supporting Information Table 1. A, PDB validation report. B, Cryo-EM data collection, 
refinement and validation statistics. 
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1 Overall quality at a glance iO
The following experimental techniques were used to determine the structure:
ELECTRON MICROSCOPY
The reported resolution of this entry is 3.30 Å.
Percentile scores (ranging between 0-100) for global validation metrics of the entry are shown in
the following graphic. The table shows the number of entries on which the scores are based.
Metric
Whole archive
(#Entries)
EM structures
(#Entries)
Clashscore 136327 1886
Ramachandran outliers 132723 1663
Sidechain outliers 132532 1531
The table below summarises the geometric issues observed across the polymeric chains. The red,
orange, yellow and green segments on the bar indicate the fraction of residues that contain outliers
for >=3, 2, 1 and 0 types of geometric quality criteria. A grey segment represents the fraction
of residues that are not modelled. The numeric value for each fraction is indicated below the
corresponding segment, with a dot representing fractions <=5%
Mol Chain Length Quality of chain
1 P 38
2 N 138
3 A 394
4 B 350
5 G 71
6 R 490
7 E 149
Page 3 Full wwPDB/EMDataBank EM Map/Model Validation Report 6E3Y
2 Entry composition iO
There are 7 unique types of molecules in this entry. The entry contains 9434 atoms, of which 0
are hydrogens and 0 are deuteriums.
In the tables below, the AltConf column contains the number of residues with at least one atom
in alternate conformation and the Trace column contains the number of residues modelled with at
most 2 atoms.
 Molecule 1 is a protein called Calcitonin gene-related peptide 1.
Mol Chain Residues Atoms AltConf Trace
1 P 35
Total C N O S
240 149 45 44 2
0 1
There is a discrepancy between the modelled and reference sequences:
Chain Residue Modelled Actual Comment Reference
P 38 NH2 - amidation UNP P06881
 Molecule 2 is a protein called Nanobody 35.
Mol Chain Residues Atoms AltConf Trace
2 N 126
Total C N O S
961 599 168 188 6
0 0
 Molecule 3 is a protein called Guanine nucleotide-binding protein G(s) subunit alpha isoforms
short.
Mol Chain Residues Atoms AltConf Trace
3 A 188
Total C N O S
1578 1009 290 274 5
0 0
There are 8 discrepancies between the modelled and reference sequences:
Chain Residue Modelled Actual Comment Reference
A 54 ASN SER conﬂict UNP P63092
A 226 ALA GLY conﬂict UNP P63092
A 268 ALA GLU conﬂict UNP P63092
A 271 LYS ASN conﬂict UNP P63092
A 274 ASP LYS conﬂict UNP P63092
A 280 LYS ARG conﬂict UNP P63092
A 284 ASP THR conﬂict UNP P63092
A 285 THR ILE conﬂict UNP P63092
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 Molecule 4 is a protein called Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit
beta-1.
Mol Chain Residues Atoms AltConf Trace
4 B 336
Total C N O S
2545 1573 455 496 21
0 0
There are 11 discrepancies between the modelled and reference sequences:
Chain Residue Modelled Actual Comment Reference
B -9 MET - initiating methionine UNP P62873
B -8 HIS - expression tag UNP P62873
B -7 HIS - expression tag UNP P62873
B -6 HIS - expression tag UNP P62873
B -5 HIS - expression tag UNP P62873
B -4 HIS - expression tag UNP P62873
B -3 HIS - expression tag UNP P62873
B -2 GLY - expression tag UNP P62873
B -1 SER - expression tag UNP P62873
B 0 SER - expression tag UNP P62873
B 1 GLY - expression tag UNP P62873
 Molecule 5 is a protein called Guanine nucleotide-binding protein G(I)/G(S)/G(O) subunit
gamma-2.
Mol Chain Residues Atoms AltConf Trace
5 G 49
Total C N O S
372 234 63 72 3
0 0
 Molecule 6 is a protein called Calcitonin gene-related peptide type 1 receptor.
Mol Chain Residues Atoms AltConf Trace
6 R 346
Total C N O S
2813 1859 459 471 24
0 0
There are 50 discrepancies between the modelled and reference sequences:
Chain Residue Modelled Actual Comment Reference
R -9 MET - initiating methionine UNP Q16602
R -8 LYS - expression tag UNP Q16602
R -7 THR - expression tag UNP Q16602
R -6 ILE - expression tag UNP Q16602
R -5 ILE - expression tag UNP Q16602
R -4 ALA - expression tag UNP Q16602
Continued on next page...
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Continued from previous page...
Chain Residue Modelled Actual Comment Reference
R -3 LEU - expression tag UNP Q16602
R -2 SER - expression tag UNP Q16602
R -1 TYR - expression tag UNP Q16602
R 0 ILE - expression tag UNP Q16602
R 1 PHE - expression tag UNP Q16602
R 2 CYS - expression tag UNP Q16602
R 3 LEU - expression tag UNP Q16602
R 4 VAL - expression tag UNP Q16602
R 5 PHE - expression tag UNP Q16602
R 6 ALA - expression tag UNP Q16602
R 7 ASP - expression tag UNP Q16602
R 8 TYR - expression tag UNP Q16602
R 9 LYS - expression tag UNP Q16602
R 10 ASP - expression tag UNP Q16602
R 11 ASP - expression tag UNP Q16602
R 12 ASP - expression tag UNP Q16602
R 13 ASP - expression tag UNP Q16602
R 14 LEU - expression tag UNP Q16602
R 15 GLU - expression tag UNP Q16602
R 16 VAL - expression tag UNP Q16602
R 17 LEU - expression tag UNP Q16602
R 18 PHE - expression tag UNP Q16602
R 19 GLN - expression tag UNP Q16602
R 20 GLY - expression tag UNP Q16602
R 21 PRO - expression tag UNP Q16602
R 462 PRO - expression tag UNP Q16602
R 463 ALA - expression tag UNP Q16602
R 464 GLY - expression tag UNP Q16602
R 465 LEU - expression tag UNP Q16602
R 466 GLU - expression tag UNP Q16602
R 467 VAL - expression tag UNP Q16602
R 468 LEU - expression tag UNP Q16602
R 469 PHE - expression tag UNP Q16602
R 470 GLN - expression tag UNP Q16602
R 471 GLY - expression tag UNP Q16602
R 472 PRO - expression tag UNP Q16602
R 473 HIS - expression tag UNP Q16602
R 474 HIS - expression tag UNP Q16602
R 475 HIS - expression tag UNP Q16602
R 476 HIS - expression tag UNP Q16602
R 477 HIS - expression tag UNP Q16602
R 478 HIS - expression tag UNP Q16602
Continued on next page...
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Continued from previous page...
Chain Residue Modelled Actual Comment Reference
R 479 HIS - expression tag UNP Q16602
R 480 HIS - expression tag UNP Q16602
 Molecule 7 is a protein called Receptor activity-modifying protein 1.
Mol Chain Residues Atoms AltConf Trace
7 E 115
Total C N O S
925 600 158 160 7
0 0
There are 27 discrepancies between the modelled and reference sequences:
Chain Residue Modelled Actual Comment Reference
E 0 MET - initiating methionine UNP O60894
E 1 LYS - expression tag UNP O60894
E 2 THR - expression tag UNP O60894
E 3 ILE - expression tag UNP O60894
E 4 ILE - expression tag UNP O60894
E 5 ALA - expression tag UNP O60894
E 6 LEU - expression tag UNP O60894
E 7 SER - expression tag UNP O60894
E 8 TYR - expression tag UNP O60894
E 9 ILE - expression tag UNP O60894
E 10 PHE - expression tag UNP O60894
E 11 CYS - expression tag UNP O60894
E 12 LEU - expression tag UNP O60894
E 13 VAL - expression tag UNP O60894
E 14 PHE - expression tag UNP O60894
E 15 ALA - expression tag UNP O60894
E 16 ASP - expression tag UNP O60894
E 17 TYR - expression tag UNP O60894
E 18 LYS - expression tag UNP O60894
E 19 ASP - expression tag UNP O60894
E 20 ASP - expression tag UNP O60894
E 21 ASP - expression tag UNP O60894
E 22 ASP - expression tag UNP O60894
E 23 LYS - expression tag UNP O60894
E 24 HIS - expression tag UNP O60894
E 25 GLY - expression tag UNP O60894
E 26 SER - expression tag UNP O60894
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3 Residue-property plots iO
These plots are drawn for all protein, RNA and DNA chains in the entry. The ﬁrst graphic for
a chain summarises the proportions of the various outlier classes displayed in the second graphic.
The second graphic shows the sequence view annotated by issues in geometry. Residues are color-
coded according to the number of geometric quality criteria for which they contain at least one
outlier: green = 0, yellow = 1, orange = 2 and red = 3 or more. Stretches of 2 or more consecutive
residues without any outlier are shown as a green connector. Residues present in the sample, but
not in the model, are shown in grey.
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• Molecule 3: Guanine nucleotide-binding protein G(s) subunit alpha isoforms short
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• Molecule 4: Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-1
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• Molecule 5: Guanine nucleotide-binding protein G(I)/G(S)/G(O) subunit gamma-2
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• Molecule 6: Calcitonin gene-related peptide type 1 receptor
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• Molecule 7: Receptor activity-modifying protein 1
Chain E:
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L
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4 Experimental information iO
Property Value Source
Reconstruction method SINGLE PARTICLE Depositor
Imposed symmetry POINT, C1 Depositor
Number of particles used 407000 Depositor
Resolution determination method FSC 0.143 CUT-OFF Depositor
CTF correction method NONE; phase plate CTF correction Depositor
Microscope FEI TITAN KRIOS Depositor
Voltage (kV) 300 Depositor
Electron dose (e−/Å
2
) 50.0 Depositor
Minimum defocus (nm) Not provided Depositor
Maximum defocus (nm) Not provided Depositor
Magniﬁcation 47170 Depositor
Image detector GATAN K2 SUMMIT (4k x 4k) Depositor
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5 Model quality iO
5.1 Standard geometry iO
Bond lengths and bond angles in the following residue types are not validated in this section:
NH2
The Z score for a bond length (or angle) is the number of standard deviations the observed value
is removed from the expected value. A bond length (or angle) with |Z| > 5 is considered an
outlier worth inspection. RMSZ is the root-mean-square of all Z scores of the bond lengths (or
angles).
Mol Chain
Bond lengths Bond angles
RMSZ #|Z| >2 RMSZ #|Z| >2
1 P 0.32 0/241 0.53 0/325
2 N 0.43 0/981 0.58 0/1329
3 A 0.38 0/1610 0.54 0/2162
4 B 0.43 0/2592 0.60 0/3519
5 G 0.31 0/378 0.51 0/513
6 R 0.38 0/2893 0.60 1/3942 (0.0%)
7 E 0.33 0/952 0.53 0/1299
All All 0.39 0/9647 0.58 1/13089 (0.0%)
There are no bond length outliers.
All (1) bond angle outliers are listed below:
Mol Chain Res Type Atoms Z Observed(o) Ideal(o)
6 R 252 LEU CA-CB-CG 5.33 127.55 115.30
There are no chirality outliers.
There are no planarity outliers.
5.2 Too-close contacts iO
In the following table, the Non-H and H(model) columns list the number of non-hydrogen atoms
and hydrogen atoms in the chain respectively. The H(added) column lists the number of hydrogen
atoms added and optimized by MolProbity. The Clashes column lists the number of clashes within
the asymmetric unit, whereas Symm-Clashes lists symmetry related clashes.
Mol Chain Non-H H(model) H(added) Clashes Symm-Clashes
1 P 240 0 243 6 0
2 N 961 0 928 9 0
3 A 1578 0 1552 10 0
Continued on next page...
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Continued from previous page...
Mol Chain Non-H H(model) H(added) Clashes Symm-Clashes
4 B 2545 0 2427 32 0
5 G 372 0 367 2 0
6 R 2813 0 2778 27 0
7 E 925 0 903 9 0
All All 9434 0 9198 83 0
The all-atom clashscore is deﬁned as the number of clashes found per 1000 atoms (including
hydrogen atoms). The all-atom clashscore for this structure is 4.
All (83) close contacts within the same asymmetric unit are listed below, sorted by their clash
magnitude.
Atom-1 Atom-2
Interatomic
distance (Å)
Clash
overlap (Å)
6:R:297:PRO:HB3 7:E:130:THR:HG21 1.74 0.68
4:B:71:VAL:HG22 4:B:81:ILE:HG12 1.77 0.65
3:A:313:PRO:O 3:A:317:ARG:NH1 2.32 0.63
6:R:172:GLN:HE21 6:R:252:LEU:HB2 1.65 0.61
4:B:95:LEU:HD13 4:B:100:VAL:HG21 1.83 0.61
1:P:33:GLY:O 6:R:121:TRP:NE1 2.33 0.61
2:N:29:PHE:O 2:N:72:ARG:NH2 2.34 0.60
1:P:17:SER:O 6:R:202:GLN:NE2 2.35 0.60
4:B:325:MET:O 4:B:340:ASN:ND2 2.36 0.59
3:A:362:HIS:NE2 3:A:378:ASP:OD2 2.35 0.59
4:B:315:VAL:HA 4:B:331:SER:HA 1.85 0.58
3:A:233:LYS:NZ 4:B:228:ASP:OD2 2.35 0.58
4:B:137:ARG:NE 4:B:171:ILE:O 2.36 0.58
4:B:271:CYS:HB2 4:B:290:ASP:HB3 1.85 0.58
6:R:379:LEU:HA 6:R:382:THR:HG22 1.86 0.57
6:R:243:VAL:HG11 7:E:142:LYS:HE2 1.88 0.55
4:B:230:ASN:ND2 4:B:246:ASP:OD1 2.38 0.55
2:N:52:SER:HB3 2:N:57:SER:HB3 1.89 0.55
2:N:52:SER:O 2:N:72:ARG:NH1 2.39 0.54
4:B:26:ALA:HB2 4:B:259:GLN:HE22 1.73 0.54
2:N:22:CYS:HB3 2:N:79:LEU:HB3 1.89 0.53
2:N:106:ASP:OD2 3:A:279:ASN:ND2 2.40 0.53
1:P:35:LYS:O 6:R:119:ARG:NH2 2.42 0.53
4:B:218:CYS:SG 5:G:18:GLN:NE2 2.81 0.52
4:B:51:LEU:HB2 4:B:336:LEU:HB2 1.91 0.52
6:R:270:HIS:HA 6:R:293:ILE:HD11 1.90 0.52
3:A:318:TYR:O 3:A:336:ARG:NH2 2.42 0.52
3:A:274:ASP:OD1 3:A:278:ASN:ND2 2.43 0.52
7:E:105:PRO:O 7:E:109:ARG:NH1 2.39 0.52
Continued on next page...
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Atom-1 Atom-2
Interatomic
distance (Å)
Clash
overlap (Å)
4:B:210:LEU:HD22 4:B:255:LEU:HD22 1.91 0.51
6:R:235:ILE:HD11 7:E:134:THR:HG23 1.92 0.51
7:E:59:TRP:HB2 7:E:109:ARG:HE 1.75 0.51
1:P:2:CYS:O 1:P:11:ARG:NH1 2.42 0.50
6:R:274:ARG:HE 6:R:290:LEU:HD23 1.76 0.50
4:B:145:TYR:O 4:B:162:GLY:N 2.45 0.50
6:R:209:PRO:HG2 6:R:212:CYS:HB2 1.94 0.49
6:R:85:MET:HA 6:R:101:VAL:O 2.12 0.49
4:B:212:ASP:OD2 4:B:219:ARG:NH2 2.45 0.49
1:P:10:HIS:O 6:R:286:SER:OG 2.30 0.49
6:R:231:LEU:HB2 6:R:301:ALA:HB1 1.94 0.49
6:R:171:CYS:SG 6:R:172:GLN:N 2.85 0.49
3:A:283:ARG:O 3:A:357:HIS:ND1 2.46 0.48
4:B:228:ASP:OD1 4:B:228:ASP:N 2.41 0.48
7:E:36:LEU:HD22 7:E:73:THR:HG22 1.96 0.48
5:G:44:HIS:ND1 5:G:47:GLU:OE2 2.38 0.48
7:E:116:GLY:HA2 7:E:119:LEU:HB3 1.96 0.47
6:R:227:TYR:HD2 6:R:298:ILE:HD13 1.80 0.47
6:R:382:THR:HA 6:R:386:PHE:HD2 1.79 0.47
2:N:63:SER:O 2:N:67:ARG:NH2 2.48 0.47
4:B:68:ARG:HH11 4:B:85:TYR:HD2 1.61 0.46
4:B:208:ALA:HB3 4:B:222:PHE:HB2 1.98 0.46
6:R:229:TRP:CE3 6:R:259:GLY:HA3 2.51 0.46
4:B:251:ARG:NH1 4:B:263:THR:OG1 2.49 0.45
4:B:165:THR:HG22 4:B:181:THR:HG22 1.97 0.45
4:B:58:ILE:HD13 4:B:336:LEU:HG 1.99 0.45
6:R:103:LYS:HB2 6:R:122:THR:HG23 1.99 0.45
2:N:15:GLY:HA2 2:N:85:SER:HA 1.99 0.44
4:B:296:VAL:O 4:B:305:ALA:N 2.49 0.44
2:N:102:PRO:HG2 4:B:247:ASP:HA 1.99 0.43
6:R:348:GLU:HG3 6:R:372:LEU:HD12 1.99 0.43
3:A:279:ASN:HD22 3:A:280:LYS:H 1.66 0.43
4:B:250:CYS:HB2 4:B:264:TYR:HB2 2.00 0.43
6:R:305:ASN:HB3 6:R:345:LEU:HB3 2.00 0.43
3:A:281:TRP:HH2 4:B:292:PHE:HE1 1.66 0.43
4:B:119:ASN:ND2 4:B:144:GLY:O 2.50 0.43
4:B:245:SER:OG 4:B:246:ASP:N 2.51 0.43
4:B:81:ILE:HD12 4:B:91:HIS:HB2 2.01 0.42
6:R:190:VAL:HA 6:R:193:ILE:HG12 2.00 0.42
6:R:278:TYR:CD2 6:R:280:ASP:HB2 2.54 0.42
1:P:16:LEU:HD23 1:P:16:LEU:HA 1.88 0.42
Continued on next page...
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Atom-1 Atom-2
Interatomic
distance (Å)
Clash
overlap (Å)
4:B:320:VAL:HG22 4:B:327:VAL:HG22 2.01 0.42
4:B:231:ALA:HB3 4:B:275:SER:HA 2.01 0.42
7:E:121:PRO:HA 7:E:124:VAL:HG22 2.01 0.42
2:N:9:GLY:HA2 2:N:124:VAL:HG22 2.02 0.41
6:R:141:LEU:HD23 6:R:144:LEU:HD21 2.02 0.41
6:R:377:GLY:HA2 6:R:380:VAL:HG12 2.02 0.41
6:R:348:GLU:HA 6:R:351:LEU:HB2 2.02 0.41
4:B:225:HIS:NE2 4:B:243:THR:OG1 2.36 0.41
6:R:84:SER:O 6:R:102:THR:HA 2.20 0.41
3:A:40:THR:HG23 3:A:220:HIS:HD2 1.84 0.41
4:B:59:TYR:HB2 4:B:75:GLN:HE21 1.86 0.41
4:B:79:LEU:HB3 4:B:93:ILE:HB 2.02 0.41
7:E:53:GLU:HA 7:E:56:TRP:CE2 2.56 0.41
There are no symmetry-related clashes.
5.3 Torsion angles iO
5.3.1 Protein backbone iO
In the following table, the Percentiles column shows the percent Ramachandran outliers of the
chain as a percentile score with respect to all PDB entries followed by that with respect to all EM
entries.
The Analysed column shows the number of residues for which the backbone conformation was
analysed, and the total number of residues.
Mol Chain Analysed Favoured Allowed Outliers Percentiles
1 P 31/38 (82%) 29 (94%) 2 (6%) 0 100 100
2 N 124/138 (90%) 120 (97%) 4 (3%) 0 100 100
3 A 176/394 (45%) 176 (100%) 0 0 100 100
4 B 334/350 (95%) 317 (95%) 17 (5%) 0 100 100
5 G 47/71 (66%) 47 (100%) 0 0 100 100
6 R 336/490 (69%) 329 (98%) 7 (2%) 0 100 100
7 E 113/149 (76%) 113 (100%) 0 0 100 100
All All 1161/1630 (71%) 1131 (97%) 30 (3%) 0 100 100
There are no Ramachandran outliers to report.
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5.3.2 Protein sidechains iO
In the following table, the Percentiles column shows the percent sidechain outliers of the chain
as a percentile score with respect to all PDB entries followed by that with respect to all EM
entries.
The Analysed column shows the number of residues for which the sidechain conformation was
analysed, and the total number of residues.
Mol Chain Analysed Rotameric Outliers Percentiles
1 P 26/29 (90%) 26 (100%) 0 100 100
2 N 104/115 (90%) 104 (100%) 0 100 100
3 A 166/349 (48%) 163 (98%) 3 (2%) 62 81
4 B 270/291 (93%) 269 (100%) 1 (0%) 92 95
5 G 39/58 (67%) 39 (100%) 0 100 100
6 R 306/437 (70%) 303 (99%) 3 (1%) 78 87
7 E 98/129 (76%) 98 (100%) 0 100 100
All All 1009/1408 (72%) 1002 (99%) 7 (1%) 86 91
All (7) residues with a non-rotameric sidechain are listed below:
Mol Chain Res Type
3 A 279 ASN
3 A 317 ARG
3 A 336 ARG
4 B 155 ASN
6 R 208 ASN
6 R 226 ASN
6 R 388 ASN
Some sidechains can be ﬂipped to improve hydrogen bonding and reduce clashes. All (13) such
sidechains are listed below:
Mol Chain Res Type
1 P 10 HIS
3 A 23 ASN
3 A 278 ASN
3 A 279 ASN
4 B 88 ASN
4 B 155 ASN
4 B 259 GLN
4 B 268 ASN
Continued on next page...
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Mol Chain Res Type
5 G 18 GLN
6 R 50 GLN
6 R 54 GLN
6 R 172 GLN
6 R 388 ASN
5.3.3 RNA iO
There are no RNA molecules in this entry.
5.4 Non-standard residues in protein, DNA, RNA chains iO
There are no non-standard protein/DNA/RNA residues in this entry.
5.5 Carbohydrates iO
There are no carbohydrates in this entry.
5.6 Ligand geometry iO
There are no ligands in this entry.
5.7 Other polymers iO
There are no such residues in this entry.
5.8 Polymer linkage issues iO
There are no chain breaks in this entry.
B 
 
Cryo-EM data collection, refinement and validation statistics 
 
 #1 name 
(EMDB EMD-8978) 
(PDB 6E3Y) 
 
 
 
Data collection and processing   
Magnification    47170  
Voltage (kV) 300  
Electron exposure (e–/Å2) 50  
Defocus range (µm) -0.6  
Pixel size (Å) 1.06  
Symmetry imposed C1  
Initial particle images (no.) 1,205,000  
Final particle images (no.) 407,000  
Map resolution (Å) 
    FSC threshold                                                             
3.26 
0.143 
 
Map resolution range (Å) 3.0-3.8  
   
Refinement   
Initial model used (PDB code) 5UZ7, 4RWG, 6B3J  
Model resolution (Å) 
    FSC threshold 
 
0.143 
 
Model resolution range (Å) 3.26  
Map sharpening B factor (Å2) -50  
Model composition 
    Non-hydrogen atoms 
    Protein residues 
    Ligands 
 
 
1195 
 
B factors (Å2) 
    Protein 
    Ligand 
93-229 (avr. 148)  
R.m.s. deviations 
    Bond lengths (Å) 
    Bond angles (°) 
 
0.007 
0.999 
 
 Validation 
    MolProbity score 
    Clashscore 
    Poor rotamers (%)    
 
1.34 
4.51 
0 
 
 Ramachandran plot 
    Favored (%) 
    Allowed (%) 
    Disallowed (%) 
 
97.41 
2.59 
0 
 
 
 
 
 
Supporting Information Table 2. Hydrogen bonds and contacts formed between 
RAMP1 and CLR during molecular dynamics simulations. Persistence is defined as 
following: (total number of hydrogen bonds between two given residues / total number of 
frames) * 100; a persistence > 100% is possible when more than one hydrogen bond is 
observed between the two residues in a given frame. Hydrogen bonds with persistence > 
1% and contacts with persistence > 20% are shown. If not specified, a side chain-side chain 
hydrogen bond is reported, otherwise bb=backbone-backbone hydrogen bond; sb=side 
chain-backbone; bs=backbone-side chain; tb=terminus-backbone. Interactions to ECL2 
(Y2774.67-H2895.66) and ECL3 (G3466.50-V3647.37) of CLR are shown in green and blue, 
respectively; interactions to the CLR ECD (E29ECD-T131ECD) are shown in grey. Interactions 
for the alternative RAMP1 C-terminus conformation are shown in italics for residues S141R 
– V148R. CLR residues involved in hydrogen bonds with persistence grater than 25 are 
shown in bold; CLR residues involved in multiple hydrogen bonds to a given RAMP1 residue 
and for which the sum of the persistence is greater than 25 are shown in bold and are 
underlined.	CLR residues involved in contacts with  persistence greater than 50 are shown 
in bold and are underlined. 
 
RAMP1 
residue 
CLR hydrogen 
bonds (% frames) 
CLR contacts (% 
frames) 
Glu29 Arg119 34.56 Arg119 27.3 
Cys57 / Tyr46 35.8 
Trp59 Thr43 16.66 
Asn39 1.90 
Thr43 100.0 
Tyr46 99.5 
Met42 96.2 
Ile63 / Asn39 98.2 
Met42 90.0 
Thr43 68.5 
Tyr66 Gln45 6.57 Gln45 100.0 
Met42 99.8 
Tyr46 99.3 
Tyr49 89.3 
Arg67 / Met42 99.8 
Arg38 95.0 
Asn39 26.2 
Ala70 / Met42 95.5 
Gln45 77.2 
Arg38 27.3 
Asp71 Arg38 75.84 Arg38 78.6 
Phe83 / Arg119 91.9 
Ser117 34.5 
Trp84 Arg119 2.38 (bs) Met 42 21.4 
Arg119 20.7 
Pro85 Arg119 2.39 (bs) Gly71 78.8 
Asp70 69.8 
Arg119 27.1 
Trp69 27.1 
Asn86 / Arg119 31.5 
Asp90 Tyr49 64.91 Tyr49 100.0 
Thr68 20.2 
Phe93 / Tyr49 99.2 
Gln45 89.5 
Leu94 / Ile52 99.8 
Met53 99.4 
Tyr49 93.1 
His97 Gln50 55.75 Gln50 100.0 
Tyr49 100.0 
Tyr46 100.0 
Met53 95.8 
Gly98 / Met53 91.1 
Phe101 / Gln50 100.0 
Tyr46 99.3 
Met53 58.7 
Arg102 Asp55 65.81  
Gln54 1.04 
Met53 92.7 
Asp55 64.5 
Gln54 31.3 
Cys104 / Gln50 99.8 
Tyr46 69.6 
Pro105 Tyr46 15.19 (bs) 
Gln50 10.49 (bs) 
Gln50 99.6 
Ile106 / Tyr46 41.3 
Ser107 Glu47 25.19 Glu47 94.9 
Lys51 35.8 
Gly108 Glu47 23.90 (bs) Glu47 87.9 
Arg109 / Thr43 88.3 
Tyr46 75.3 
Glu47 67.8 
Ala110 Glu47 24.24 (bs) Thr43 90.0 
Glu47 67.6 
Val111 / Tyr278 89.5 
Tyr277 40.2 
Lys40 22.7 
Arg112 Glu47 101.94 
Asp90 10.80 
Glu47 83.4 
Tyr278 72.0 
Tyr277 41.8 
Asp113 Thr288 49.20 
His289 33.99 (sb) 
Tyr278 32.81  
His289 18.00 
His289 86.3 
Tyr278 73.6 
Thr288 72.3 
Leu290 47.7 
Tyr277 21.7 
Pro114 / Tyr277 91.1 
Leu290 85.1 
Tyr278 35.4 
Ile118 / Tyr277 53.0 
Leu119 / His289 93.6 
Leu290 80.1 
Ile293 28.4 
Phe122 / Ile293 94.7 
Ile269 82.7 
Ala273 71.7 
Tyr277 54.1 
Leu290 35.5 
Leu276 23.4 
Ile272 22.3 
Ile123 / Tyr292 99.6 
Ile293 92.1 
His289 55.5 
Pro126 / Pro297 98.5 
Ile293 96.8 
Pro266 83.6 
Ile269 68.5 
Ile127  / Gly296 98.4 
Pro297 97.1 
Ala300 95.7 
Val129 / Phe262 97.5 
Thr130 / Phe262 99.8 
Pro297 99.6 
Phe228 97.6 
Ala300 72.2 
Ala301 30.5 
Leu131 / Ala300 78.0 
Val304 66.4 
Val133 / Leu258 99.0 
Phe262 90.1 
Phe257 67.9 
Thr134 / Leu231 98.9 
Ile235 98.8 
Val302 95.6 
Leu258 68.5 
Leu136 / Trp254 67.9 
Val137 / Trp254 99.4 
Leu258 98.3 
Ile235 95.6 
Tyr255 88.8 
Phe257 26.5 
Val138 / Ile235 99.2 
Phe308 86.1 
His238 22.5 
Gln140 / Trp254 98.0 
His251 22.2 
Ser141 Tyr255 22.72  
Thr239 6.24 
 
 
 
 
Thr239 12.37 (bs) 
Tyr255 8.55 
Thr239 6.54 
Gln250 6.19 (bs) 
Tyr255 2.97 
Thr239 91.2 
Tyr255 86.6 
Ile235 75.1 
Gln250 54.9 
His251 29.4 
 
Tyr255 95.5 
Thr239 92.3 
Ile235 84.5 
Gln250 69.0 
Lys142  Glu248 1.47 
 
 
 
Val243 92.1 
Thr239 66.0 
Ala244 50.5 
 
Val243 89.8 
Ala244 78.8 
Thr239 72.4 
Arg143 Gln250 1.15 (bs) 
 
Gln250 1.41 (bs) 
 
/ 
 
Gln250 34.7 
His251 20.4 
Thr144 Lys249 2.35 (sb) 
 
 
 
 
Lys249 1.67 (bs) 
Lys249 35.2 
Ala247 34.7 
Phe246 22.0 
Gln250 21.1 
 
Ala247 49.3 
Phe246 42.2 
Gln250 39.5 
Ala244 35.5 
Lys249 28.1 
Glu145 Lys 249 4.61 
 
 
Lys249 3.76 
Lys249 3.66 (bb) 
Lys249 23.7 
His251 20.2 
 
Gln250 41.4 
Lys249 39.0 
His251 35.8 
Gly146 Trp254 2.24 (bs) 
 
His251 1.62 (sb) 
Lys249 22.4 
 
His251 24.2 
Ile147 / 
 
/ 
His251 26.3 
 
His251 20.9 
Val148 Lys249 3.75 
His251 2.89 (sb) 
 
Lys249 2.19 
His251 24.5 
 
 
 
	
	
  
Supporting Information Table 3. Hydrogen bonds and contacts formed between 
CGRP and CLR/RAMP1 during molecular dynamics simulations. Persistence is defined 
as the (total number of hydrogen bonds between two given residues / total number of 
frames) * 100; a persistence > 100% is possible when more than one hydrogen bond is 
observed between the two residues in a given frame. Hydrogen bonds with persistence > 
1% and contacts with persistence > 20% are shown. If not specified, a side chain-side chain 
hydrogen bond is reported, otherwise bb=backbone-backbone hydrogen bond; sb=side 
chain-backbone; bs=backbone-side chain; tb=terminus-backbone. Interactions to ECL1 
(T1962.69-P2093.74), ECL2 (Y2774.67-H2895.66) and ECL3 (G3466.50-V3647.37) of CLR are 
shown in red, green and blue respectively; interactions to the CLR ECD (Q33ECD-T131ECD) 
are shown in grey. CLR residues involved in multiple hydrogen bonds to a given CGRP 
residue and for which the sum of the persistence is greater than 25 are shown in bold and 
are underlined. 
 
CGRP residue CLR hydrogen 
bonds  
(% frames) 
CLR contacts 
(% frames) 
RAMP1 
hydrogen 
bonds (% 
frames) 
RAMP1 
contacts  
(% frames) 
A1 Asp287 3.76 
(bs) 
His289 3.71 
(bs) 
Asp366 2.59 
(bs) 
Asp287 52.4 
Ser286 37.1 
Tyr292 34.7 
His289 27.8 
Arg355 27.5 
/ / 
C2 Arg355 1.29 
(bs) 
Ser286 65.7 
Leu291 63.4 
Tyr292 47.1 
His295 24.2 
/ / 
D3 Arg355 34.71 
Tyr292 7.50 
Lys359 3.78 
Arg355 79.0 
Trp354 62.4 
Tyr292 42.5 
/ / 
T4 His295 1.19 His295 74.0 
Trp354 47.8 
Cys299 35.0 
Tyr292 26.8 
/ / 
A5 / Phe349 84.5 
Met373 62.6 
Met369 57.4 
Trp354 42.2 
Tyr227 21.9 
/ / 
T6 His295 31.13 His295 81.5 
Ile298 74.6 
Tyr227 70.5 
Met223 68.8 
Met373 38.2 
Phe349 35.9 
Leu302 27.0 
/ / 
C7 / His295 60.3 
Leu291 60.3 
Ser286 45.6 
/ / 
V8 / His370 96.4 
Met373 95.9 
/ / 
Met369 71.0 
His374 33.7 
Trp354 24.6 
T9 His219 18.98 
His374 2.16 
Thr191 92.7 
Leu195 87.0 
His219 76.9 
His194 59.6 
Met373 52.7 
His374 51.6 
Met223 37.2 
/ / 
H10 His295 7.46 
Arg274 2.48 
Ser286 91.1 
Ile284 69.8 
Leu220 69.3 
Leu291 69.2 
Gln216 69.1 
His219 62.9 
His295 44.7 
His194 43.3 
Trp283 26.2 
Met223 23.9 
Ser285 21.7 
/ / 
R11 Asp366 85.37 
Asp96 8.37 
Asp287 6.24 
Ser286 73.6 
Asp366 71.3 
His370 61.6 
Trp354 25.1 
/ / 
L12 / Leu141 97.4 
Leu195 95.4 
Thr145 85.3 
His370 83.6 
Phe142 65.9 
His374 61.3 
Ala138 43.0 
/ / 
A13 / Leu195 95.2 
Ile284 90.8 
His194 71.9 
Ala199 54.5 
Val198 49.9 
/ / 
G14 / Ile284 77.0 
Ser286 22.5 
/ / 
L15 / Ala138 99.2 
Lys134 67.3 
Leu141 48.5 
/ / 
L16 / Phe142 99.6 
Ala199 98.2 
Leu195 90.3 
Ala138 74.1 
Leu139 58.1 
Val198 38.9 
Asn200 36.7 
/ / 
S17 Gln202 2.95 
(bs) 
Ile284 68.2 
Gln202 63.4 
Ala199 59.4 
/ / 
Val198 47.5 
Leu204 32.0 
Val205 28.8 
R18 Asp287 22.96 
Asp90 4.47 
Asp96 4.31 
Pro97 92.2 
Gln93 87.6 
Phe95 52.5 
Asp96 51.7 
Asp90 34.8 
Asp287 23.9 
/ / 
S19 Gln93 7.74 
(sb) 
Val135 99.5 
Ala138 75.9 
Leu139 28.1 
/ / 
G20 / Gln202 68.7 / / 
G21 / Gln93 78.2 
Gln202 53.8 
/ / 
V22 / Val135 91.3 
Asp94 90.1 
Gln93 87.5 
Thr131 79.3 
His132 36.8 
/ / 
V23 / Val135 83.8 
Leu139 60.0 
/ / 
K24 Gln202 1.45 Gln202 65.2 / / 
N25 / / / / 
N26 / / / / 
F27 / Asp94 90.8 
Gln93 73.7 
/ / 
V28 / / / / 
P29 / Asp94 89.2 
Asn128 21.6 
/ / 
T30 Asp94 62.32 
Asp94 56.01 
(bs) 
Asp94 96.7 
Asn128 93.4 
Phe95 93.2 
Phe92 92.9 
Trp72 75.6 
/ / 
N31 / Trp72 77.6 / / 
V32 / Tyr124 93.2 
Phe95 92.2 
Thr125 90.5 
Asn128 88.1 
Trp72 67.1 
Trp121 50.6 
/ / 
G33 Trp121 17.80 
(bs) 
Trp121 55.9 / / 
S34 Arg119 6.20 
(bs) 
Ser117 3.66 
(bs) 
His114 3.33 
Trp121 51.4 
His114 49.7 
Arg119 43.0 
Ser117 40.1 
Ala116 21.1 
Trp84 1.36 Phe83 26.5 
K35 Arg119 1.07 
(bs) 
Arg119 34.4 Glu78 7.77 Phe83 55.5 
A36 R119 6.04 (bs) Trp72 54.6 / / 
Trp121 50.2 
Arg119 28.6 
F37 T122 11.48 
(tb) 
T122 8.22 (bb) 
Asp70 1.62  
Trp72 89.4 
Gly71 79.2 
Tyr124 55.6 
Asp70 52.7 
Thr122 34.5 
Trp121 30.1 
Arg119 22.8 
/ Trp84 87.9 
Pro85 78.9 
Trp74 57.7 
Phe83 22.4 
 
 
 
  
Supporting Information Table 4. The difference in hydrogen bond formation between 
CGRP and CLR, during MD simulations performed on the CGRP-CLR-Ga (371-394) 
complex in the presence and absence of RAMP1. Hydrogen bond persistence is 
expressed as percentage on the total duration of the simulations (2.0 µs for each system). 
Hydrogen bonds with persistence > 5% are shown: sb=side chain-backbone; bs=backbone-
side chain; ts=terminus-side chain. If not specified, a side chain-side chain hydrogen bond 
is reported. A persistence > 100% is possible when more than one hydrogen bond is 
possible between the two residues. The persistence of hydrogen bonds involving Asp3, Thr6, 
Thr9, His10 (and Phe37) are unchanged upon loss of RAMP1, consistent with the low RMSFs 
in this region. The main loss of interactions is in the C-terminus; this is consistent with the 
higher RMSF for this region. Moreover, this may affect the proposed two-stage binding 
mechanism for class B peptide ligandsS1 in which the initial binding involves the C-terminus.  
 
CGRP residue Hydrogen bond persistence (% frames)  Variation 
 With RAMP1 Without RAMP1  
Ala1  H289ECL2   17.4 (ts)  H289ECL2    10.0 ¯ 
Arg11 D366ECL3   108.6 D366ECL3   134.0 ­­ 
Arg18 D287ECL2   72.9 
D90ECD      14.9 
D287ECL2    45.1 
/ 
¯¯¯ 
¯ 
Ser19 Q93ECD      7.1 (sb) / ¯ 
Thr30 D94ECD      61.1 
D94ECD      54.7 (bs) 
D94ECD       31.0 
D94ECD      27.5 (bs) 
¯¯¯ 
¯¯¯ 
Persistence change: ­­= 15-30% increase; ¯= 5-15% decrease; ¯¯= 15-30%; ¯¯¯= 30+% 
decrease. Details of the CLR – CGRP and RAMP1 – CLR interactions are available from 
the University of Essex Research Repository (doi to be provided). 
 
 
  
Supporting Information Table 5. The difference in CLR intra-molecular hydrogen 
bonds formation in the presence or absence of RAMP1. Persistence during MD 
simulations performed on the CGRP-CLR-Ga(371-394) complex in the presence and 
absence of RAMP1. Hydrogen bond persistence is expressed as percentage on the total 
duration of the simulations (2.0 µs for each system). sb=side chain-backbone; 
bs=backbone-side chain. If not specified, a side chain-side hydrogen bond is reported. A 
persistence > 100% is possible when more than one hydrogen bonds are possible between 
the two residues.  
 
CLR intra-molecular 
Hydrogen bond 
Hydrogen bond persistence 
(% frames) 
Variation 
With RAMP1 Without RAMP1 
R1732.46 - E2333.50 214.5 125.2 ¯¯¯¯ 
R2744.64 - D280ECL2 157.4 5.8 ¯¯¯¯¯ 
K1341.32 - D96ECD 
K1341.32 - A1381.36 (sb) 
K1341.32 - N1301.28 (sb) 
K1341.32 - E99ECD 
70.4 
63.5 
36.7 
32.9 
38.0 
49.8 
29.9 
9.7 
¯¯¯ 
¯ 
¯ 
¯¯ 
D67ECD - D77ECD 
D67ECD - D77ECD (bs) 
D67ECD - K51ECD (sb) 
58.4 
46.9 
16.1 
77.5 
32.1 
39.1 
­­ 
¯ 
­­ 
D108ECD - R113ECD 37.6 79.2 ­­­ 
Persistence change: ­­= 15-30% increase; ­­­= 30-50% increase; ­­­­= 50-100%% 
increase; ¯= 5-15% decrease; ¯¯= 15-30%; ¯¯¯= 30-50% decrease; ¯¯¯¯= 50-100% 
decrease; ¯¯¯¯¯=>100% decrease. Values over 100% arise through multiple hydrogen 
bonds. 
 
  
Supporting Information Table 6. Summary of all the MD simulations performed on the 
CLR-CGRP-RAMP1-G-protein. CLR conformation #4 is the original PLOP-derived 
conformation; CLR conformations #0-3 were taken from the 4 highest occupied clusters. abg 
denotes the full G-protein, while a371-394 denotes the C terminal helix aH5 (N371 - L394) 
of the G-protein a subunit. 
 
Conformation G protein Number of 
replicas 
Total MD 
sampling time ECL3 
 
RAMP1  
C-term 
#0 #1 abg 4  1.6 µs 
#1 #1 abg 4 1.6 µs 
#2 #1 abg 4 1.6 µs 
#3 #1 abg 4 1.6 µs 
#1 #2 abg 10 2.4 µs 
Total CLR:CGRP:RAMP1:abg simulation time 8.8 µs 
#4 #1 (a371-394) 4 2.0 µs 
#4 N/A (a371-394) 4 2.0 µs 
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